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Synopsis 
 
Die Langerhans-Inseln als wichtiges endokrines System unseres Körpers sind als 
einzelne separate Entitäten in Mitte exokriner Azinuszellen der Bauchspeicheldrüse 
angeordnet. Diese besondere anatomische Lage inspirierte die Wissenschaft bereits im 
neunzehnten Jahrhundert, eine Beeinflussung des exokrinen Gewebes durch die Langerhans-
Inseln zu postulieren (Jarotzky, 1899). Zudem weisen seit etwa 90 Jahren ein Vielzahl von 
klinischen Untersuchungen auf eine exokrine Insuffizienz bei Diabetes mellitus Typ I und in 
geringeren Maße bei Diabetes mellitus Typ II Patienten hin (Jones et al., 1925; Frier et al., 
1976; Rathmann et al., 2001; Hardt et al., 2003; Terzin et al., 2014). Die Prävalenz exokriner 
Insuffizienz liegt bei den größten Einzelstudien mit Diabetes mellitus Typ I Patienten bei 23% 
bzw. Diabetes mellitus Typ II Patienten bei 12 % (Hardt et al., 2003; Rathmann et al., 2001). 
Um mögliche klinische Symptome dieser exokrinen Insuffizienz wie Steatorrhoe zu lindern, 
können Patienten mit Enzymen der Bauchspeicheldrüse wie z.B. Pancreatin behandelt 
werden. Einen Einfluss dieser Therapie auf klinisch relevante Symptome bei Diabetes 
assoziierter Pankreasinsuffizienz konnte jedoch in klinischen Studien nicht nachgewiesen 
werden (Ewald et al., 2007).  
Inspiriert durch die auffällige anatomische Lage der Langerhans-Inseln und den 
klinischen Befunden in Diabetes Patienten, wurden in den letzten Jahrzehnten Mechanismen 
definiert wie Langerhans-Inseln physiologische Parameter des exokrinen Gewebes regulieren. 
Eine wichtige Grundlage für das Verständnis dieser Regulation beruht auf den bereits 
frühzeitig erkannten Besonderheiten in der Blutversorgung des Pankreasgewebes (Wharton, 
1932; Thiel, 1954, Ferner, 1957). Durch ein insulo-azinäres Portalsystem fließt arterielles Blut 
zuerst zu den Langerhans-Inseln und danach in das exokrine Gewebe der 
Bauchspeicheldrüse und bildet somit eine ideale Voraussetzung für eine Kommunikation 
zwischen endokrinem und exokrinem Gewebe (Ohtani et al., 1983; Wayland 1997, Ballian and 
Brunicardi, 2007; Barreto et al., 2010). Neben diesem Portalsystem wurde auch ein insulo-
venöser Blutfluss beobachtet (Ohtani et al., 1986). Möglicherweise bewirkt dieses vaskuläre 
System, dass Hormone der Langerhans-Inseln auch rasch an den restlichen Körper 
abgegeben werden (Ohtani et al., 1986). Trotz unzähliger Studien, die den insulo-azinären 
Blutfluss belegen, wird vor allem inselfernes exokrines Pankreasgewebe auch von 
intralobulären Arteriolen, die nicht durch Langerhans-Inseln führen, mit Blut versorgt 
(Murakami et al., 1997; Barreto et al., 2010). Dies lässt die Schlussfolgerung zu, dass 
inselnahe Areale des exokrinen Gewebes durch den insulo-azinären Blutfluss auf direkten 
Wege mit hohen Konzentrationen von Hormonen der Langerhans-Inseln versorgt werden, 
während inselferne Areale vorwiegend über den systemischen Blutkreislauf und intralobuläre 
Arteriolen mit Hormonen versorgt werden (Ohtani et al., 1986; Murakami et al., 1992). Eine 
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Regulation der Physiologie des exokrinen Pankreasgewebes durch Hormone der Langerhans-
Inseln wird zudem durch die Fenestrierung der Kapillaren erleichtert. Diese Poren werden in 
den Kapillaren der Langerhans-Inseln und des exokrinen Gewebes beobachtet und erlauben 
einen raschen Austausch zwischen dem Kapillarbett und dem interstitiellen Gewebe (Kvietys 
et al. 1983).  
Vor allem durch tierexperimentelle Studien wurden relevante Hormone identifiziert und 
deren Einfluss auf exokrine Zellen charakterisiert. So bewirkt die Ablation der Insulin 
produzierenden Beta-Zellen durch Administration von z.B. Streptozotocin eine verminderte 
Expression und Sekretion von Amylase in den Azinuszellen, wobei Insulin sowohl die basale 
als auch die stimulierte Amylase Sekretion erhöht (Benabdeljlil et al., 1965; Couture et al., 
1972; Hegyi et al., 1999; Patel et al., 2004; Patel et al., 2006; Han and Liu 2010). Dieses 
Konzept einer insulinär-azinären Achse dient als wichtiges Modell für eine Erklärung der 
exokrinen Insuffizienz bei Diabetes mellitus Patienten (Williams and Goldfine, 1985; Barreto et 
al., 2010). Da zusätzlich zu Insulin auch weitere Hormone der Langerhans-Inseln wie z.B. 
Glucagon, Somatostatin und Pancreatic Polypeptide die Physiologie von Azinuszellen 
beeinflussen, wurde das ursprüngliche Modell von William und Goldfine erweitert, sodass man 
nun von einer Inselzell-Azinus-Achse spricht (Barreto et al., 2010). Diese Achse reguliert 
neben dem Nervus vagus und Hormonen des Magendarmtraktes wie z.B. Sekretin und 
Cholecystokinin die exokrine Funktion der Bauchspeicheldrüse. 
Während eine Beeinflussung des exokrinen Gewebes durch die Langerhans-Inseln und 
die Auswirkungen von Diabetes mellitus auf die Physiologie des exokrinen Pankreas seit 1899 
gut charakterisiert wurden und somit zumindest teilweise verstanden werden, ist das Wissen, 
in wie weit Diabetes mellitus weitere Pathologien des Organs wie z.B. Pankreatitiden oder das 
pankreatische duktale Adenokarzinom beeinflusst, unvollständig. Durch klinische Studien ist 
belegt, dass Patienten mit akuter oder chronischer Pankreatitis oft temporären oder 
persistierenden Diabetes mellitus entwickeln. So wird bei akuter Pankreatitis eine temporäre 
Hyperglykämie bei bis zu 50% und ein persistierender Diabetes bei bis zu 15% der Patienten 
beobachtet (Czako et al., 2009; Das et al., 2014). Die Prävalenz von Diabetes bei chronischer 
Pankreatitis liegt abhängig von der jeweiligen Studie zwischen 30 und 83% (Angelopoulos et 
al., 2005; Czako et al., 2009; Chen et al., 2011). Diese Korrelationen werden zum Teil durch 
die wohlbekannten funktionellen Einschränkungen des endokrinen Pankreasgewebes bei 
Pankreatitis, den sogenannten pankreopriven Diabetes oder Diabetes mellitus Typ IIIc erklärt 
(Czako et al., 2009).  In wie weit diese funktionelle Einschränkung des endokrinen Gewebes 
wiederum einen Einfluss auf den Verlauf von Pankreatitiden hat, ist noch wenig erforscht 
(Czako et al., 2009). Es gibt jedoch korrelative Anhaltspunkte, dass eine negative 
Beeinflussung möglich wäre. So ist z.B. Diabetes ein Risikofaktor bei akuter als auch 
chronischer Pankreatitis und Hyperglykämie ist ein Kriterium beim Ranson Score, um die 
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Schwere einer akuten Pankreatitis zu prognostizieren (Ranson et al., 1974; Renner et al., 
1985; Seicean et al., 2006, Urushihara et al., 2012). Zudem zeigte eine klinische Studie, dass 
Insulinadministration bei akuter Pankreatitis die Mortalität signifikant zu senken vermag 
(Hallberg, 1977). Um zu überprüfen, welchen Einfluss Diabetes und Insulin auf den Verlauf 
einer akuten Pankreatitis hat, verglichen wir den Verlauf Cerulein induzierter akuter 
Pankreatitis in hyperglykämen, hypoinsulinämen Mäusen mit dem Verlauf einer akuten 
Pankreatitis in normoglykämen Tieren (Zechner et al., 2012; s. Anhang Teil 1).  
Überraschender Weise kam es in den diabetischen Mäusen zu einer starken Aggravierung der 
akuten Pankreatitis. Diabetes verstärkte die Inflammation, die Ödembildung und erhöhte den 
Zelltod im Gewebe. Diabetes hemmte auch die Regeneration von Azinuszellen, führte zu einer 
verstärkten azinären zu duktalen Metaplasie und zu einer verstärkten Atrophie der 
Bauchspeicheldrüse. Diese nachteiligen Effekte konnten durch die subkutane Administration 
von Insulin behoben werden. Somit kann man schlussfolgern, dass Diabetes akute 
Pankreatitis negativ und Insulin akute Pankreatitis positiv beeinflusst. Einige wenige weitere 
Publikationen unterstützen diese Hypothese. So konnte eine britische Arbeitsgruppe belegen, 
dass Insulin den Zelltod von Azinuszellen nach Applikation von Palmitoleinsäure in vitro 
hemmt (Samad et al., 2014). Eine ungarische Arbeitsgruppe berichtete, dass Diabetes in 
Ratten die Cholecystokinin stimulierte Pankreasregeneration nach Arginin induzierter 
Pankreatitis verringert und dass Insulin die durch Cholecystokinin stimulierte Proliferation von 
Azinuszellen erhöht (Takács et al., 2001, Hegyi et al., 2004).  Insgesamt unterstützen diese 
Studien die Hypothese, dass Diabetes akute Pankreatitis verschlimmert, während Insulin das 
Gegenteil bewirkt. Laut einer Meta-Analyse beobachtet man bei 37% der Patienten mit akuter 
Pankreatitis eine Hyperglykämie, wobei jedoch nur 15% der Patienten mit Insulin behandelt 
werden (Das et al., 2014). In wie weit eine Insulinadministration einen Vorteil für weitere 
Patientengruppen darstellen könnte und ob man Hyperglykämie bei akuter Pankreatitis 
generell mit Insulin behandeln sollte, müsste nun in weiteren klinischen Studien evaluiert 
werden. 
Die molekularen Mechanismen, wie Diabetes Pankreatitis beeinflusst, werden bisher 
nur marginal verstanden. Tierexperimentelle Ansätze definierten jedoch ein sogenanntes 
Notfallprogramm während einer akuten Pankreatitis (Fiedler et al., 1998). Hierbei wird die 
Expression von Genen induziert, die den Zelltod und die Inflammation während einer 
Pankreatitis hemmen und somit einen protektiven Effekt auf die Bauchspeicheldrüse haben 
(Fiedler et al., 1998). Gene, die während dieses Notfallprogrammes induziert werden, sind z.B. 
der Ko-Transkriptionsfaktor p8, der wiederum die Expression weiterer Gene wie z.B. Reg3β 
induziert (Vasseur et al., 2004; Closa et al., 2004). Die Expression von Reg3β reduziert 
Inflammation und den Zelltod im exokrinen Gewebe und hat somit eine hemmende Wirkung 
auf den Verlauf der Pankreatitis (Zhang et al., 2004; Gironella et al., 2007). Die Expression 
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dieses protektiven Gens wird jedoch durch Diabetes gehemmt (Zechner et al., 2012; s. 
Anhang Teil 1). Ein weiteres Protein, dem eine Funktion bei inflammatorischen Erkrankungen 
aber auch bei von Diabetes mellitus verursachten Pathologien zugeschrieben wird, ist der 
Rezeptor für Advanced Glycation Endproducts (RAGE), der durch glykierte Proteine oder auch 
Proteine wie High-Mobility-Group-Protein-Box-1 (HMGB1), welches bei Nekrose freigesetzt 
wird, aktiviert wird (Yamagishi et al., 2005; Chuah et al., 2013). Während dem 
zytomembranständigen RAGE meist eine pro-inflammatorische Funktion zugesprochen wird, 
haben N-terminale proteolytische Abbauprodukte bzw. Splicevarianten, die zur Expression 
einer löslichen Isoform von RAGE (sRAGE, esRAGE) führen, eine anti-inflammatorische 
Wirkung (Ramasamy et al., 2009). Diese löslichen Isoformen von RAGE binden RAGE-
Liganden und hemmen somit deren pro-inflammatorische Wirkung (Ramasamy et al., 2009). 
Interessanter Weise reduziert Diabetes die Expression kurzer N-terminaler RAGE Isoformen in 
der entzündeten Bauchspeicheldrüse (Zechner et al., 2013; s. Anhang Teil 2). Somit könnte 
die Aggravierung akuter Pankreatitis durch Diabetes zumindest teilweise durch die Reduktion 
in der Konzentration von Reg3β und anti-inflammatorischen RAGE Isoformen im 
Pankreasgewebe erklärt werden. 
Eine akute Pankreatitis kann bei bis zu 20% von Patienten zu schweren Symptomen 
wie lokalen Nekrosen in der Bauchspeicheldrüse oder durch eine systemische Ausschüttung 
von Entzündungsmediatoren zu einem systemischen inflammatorischen Response Syndrom 
(SIRS) führen (Forsmark and Baillie, 2007). Dies führt oft zu akuten Lungenversagen und 
sogar zu multiplen Organversagen und ist teilweise verantwortlich für die beobachtete 
Mortalität bei akuter Pankreatitis. Um zu überprüfen, welchen Einfluss Diabetes auf 
systemische Inflammation und die Lunge während einer akuten Pankreatitis hat, verglichen wir 
sowohl Interleukin-6 Konzentration im Blut als auch Inflammation und Zelltod in der Lunge in 
hyperglykämen, hypoinsulinämen Mäusen mit normoglykämen Tieren (Zechner et al., 2014; s. 
Anhang Teil 3). Obwohl diabetische Tiere im Vergleich zu normoglykämen Tieren stark 
erhöhte IL-6 Konzentrationen bei akuter Pankreatitis im Blut aufwiesen, war die Anzahl  von 
Granulozyten in den Lungen dieser Tiere nur moderat erhöht, und eine signifikante Induktion 
von Zelltod konnte nicht im Lungengewebe nachgewiesen werden. Somit führte Diabetes zu 
einer wesentlichen Verschlechterung in der lokalen Symptomatik einer akuten Pankreatitis und 
in der Folge zu erhöhten Entzündungsparameter wie z.B. einer erhöhten IL-6 Konzentration im 
Blut. Diabetes führte jedoch nicht zu einer stark erhöhten Lungeninflammation bzw. einer 
Schädigung des Lungenparenchyms. Da sich diese Daten bisher nur auf ein Mausmodell 
beziehen, kann jedoch nur eingeschränkt die Schlussfolgerung gezogen werden, dass 
Diabetes generell lokale Komplikationen bei akuter Pankreatitis aggraviert, jedoch dies nicht 
die Gefahr für ein Lungenversagen erhöht. Eine derartige Schlussfolgerung wäre jedoch 
konsistent mit klinischen Studien und mit tierexperimentellen Ansätzen, die belegen, dass 
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Diabetes eine Inflammation und Lungenschädigung in unterschiedlichen Situationen meist 
nicht verstärkt, sondern hemmt (Honiden and Gong., 2009; Esper et al., 2009; Koh et al., 
2012; Filgueiras et al., 2012; Gu et al., 2014; Filgueiras et al., 2014). 
Während akute Pankreatitis vorwiegend zu temporärer Hyperglykämie führt (Czako et 
al., 2009; Das et al., 2014), entwickeln Patienten mit chronischer Pankreatitis oft einen 
persistierenden Diabetes (Angelopoulos et al., 2005; Czako et al., 2009; Chen et al., 2011). 
Um zu überprüfen, welchen Einfluss Diabetes auf den Verlauf einer chronischen Pankreatitis 
hat, verglichen wir Cerulein induzierte chronische Pankreatitis in hyperglykämen, 
hypoinsulinämen Mäusen mit chronischer Pankreatitis in normoglykämen Tieren (Zechner et 
al., 2014; s. Anhang Teil 4). Diabetes verstärkte die Infiltration inflammatorischer Zellen in das 
Pankreasgewebe, die Proliferation pankreatischer Sternzellen und die Bildung von Kollagen I. 
Diabetes erhöhte den Zelltod von Azinuszellen und führte somit zu einer verstärkten 
Pankreasatrophie. Diese Daten unterstützen die Hypothese, dass Diabetes den Verlauf 
chronischer Pankreatitis verschlimmert. In wie weit eine intensiviertere Insulintherapie vom 
Vorteil für diabetische Patienten bei chronischer Pankreatitis sein könnte, müsste jedoch 
sorgfältig in klinischen Studien evaluiert werden. Aufgrund der bei chronischer Pankreatitis 
meist vorliegenden eingeschränkten Glukagonsekretion und der damit verbundenen Gefahr 
von hypoglykämen Phasen wird meist eine konservative Insulintherapie empfohlen (Forsmark 
et al., 2007; Braganza et al., 2011; Rickels et al., 2013). Jedoch belegt eine klinische Studie, 
dass eine intensiviertere Insulintherapie bei chronischer Pankreatitis relativ gefahrlos 
durchgeführt werden kann (Terzin et al., 2012). Ob dies jedoch auch einen Vorteil für den 
Patienten darstellt, müsste noch evaluiert werden. 
Neben Pankreatitiden stellt das duktale pankreatische Adenokarzinom (PDA) eine 
weitere wichtige Erkrankung der Bauchspeicheldrüse dar. Wegen einer meist späten 
Diagnose, einer schnellen Metastasierung und einem schlechtes Ansprechen auf Therapien 
liegt die 5-Jahres-Überlebensrate dieser Erkrankung bei etwa 6-7% (Jemal et al., 2010, Lemke 
et al., 2014). Gut charakterisierte Risikofaktoren für die Entwicklung von PDA sind z.B. 
chronische Pankreatitis, aber auch Diabetes mellitus Typ 2 (Berrington et al., 2003; Huxley et 
al., 2005; Duell et al., 2012). Es ist unumstritten, dass diese Faktoren, das Risiko an PDA zu 
erkranken, erhöhen. Jedoch scheitert der Versuch, dies mechanistisch zu verstehen, am 
mangelnden Verständnis, wie sich präkanzerogene Läsionen entwickeln. Ursprünglich 
vermutete man, dass PDA sich über mehrere Zwischenstufen, den sogenannten  
pankreatischen intraepithelialen Neoplasien (PanINs), aus Gangepithel entwickeln (Kopp und 
Sander 2014). Untersuchungen an gentechnisch veränderten Mäusen zeigten jedoch, dass 
duktales Epithel kaum durch Onkogene transformiert werden kann, während die Expression 
von onkogenen K-Ras in Azinuszellen insbesondere bei gleichzeitiger chronischer Pankreatitis 
mittels azinär-duktaler Metaplasie zur Bildung von PanINs und PDA führt (Brembeck et al. 
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2003; Guerra et al., 2007; Kopp et al., 2012). Erst kürzlich wurden spezifische Ausstülpungen 
der Pankreasgänge, sogenannte Pancreatic Duct Glands (PDGs), in Mäusen und Menschen 
entdeckt (Strobel et al., 2010). Diese PDGs exprimieren Gene charakteristisch für 
Vorläuferzellen wie z.B. pdx1 und können nach Stimulation sich zu PanIN ähnlichen Strukturen 
entwickeln (Gier et al., 2012; Wang et al., 2013). Um zu überprüfen, welchen Einfluss 
Risikofaktoren wie Diabetes mellitus Typ II und chronische Pankreatitis, auf PDGs haben, 
verglichen wir PDGs in diabetischen B6.V-Lepob/ob mit PDGs in nichtdiabetischen B6.V-Lep+/? 
Mäusen nach bzw. ohne Induktion einer chronischen Pankreatitis (Bobrowski et al., 2013; s. 
Anhang Teil 5). Wir beobachteten, dass eine Diabetes Typ II ähnliche Symptomatik und 
chronische Pankreatitis die Proliferation der epithelialen Zellen spezifisch in PDGs stimulieren 
und beide Risikofaktoren Charakteristika von PDA wie z.B. nukleares S100P und Produktion 
von Mucin 5a, in diesen PDGs induzieren. PDGs stellen somit interessante Strukturen dar, aus 
denen sich PDA entwickeln könnten. Um diese Hypothese zu unterstützen, müsste man 
spezifisch in PDGs onkogenes Ras und/oder weitere Onkogene exprimieren und das 
Entstehen von PDA beobachten. Um dies technisch umzusetzen, ist jedoch zuerst eine 
weitere Charakterisierung spezifischer Genexpression in PDGs notwendig. 
Während einige Publikationen den Einfluss von Diabetes mellitus Typ II und chronische 
Pankreatitis auf potentielle präkanzerogene Läsionen im Pankreas belegen, gibt es kaum 
Informationen, wie diese Faktoren die Pathophysiologie etablierter Karzinome beeinflussen 
(Guerra et al., 2007; Strobel et al., 2010; Guerra et al., 2011; Daniluk et al., 2012; Bobrowski et 
al., 2013). Um zu überprüfen, welchen Einfluss diese Faktoren auf etablierte 
Pankreaskarzinome haben, injizierten wir 6606PDA Zellen in den Pankreaskopf von 
diabetischen B6.V-Lepob/ob und nichtdiabetischen B6.V-Lep+/? Mäusen und induzierten in 
jeweils einer Hälfte der Mäuse eine chronische Pankreatitis (Zechner et al., 2014; s. Anhang 
Teil 6). Wir beobachteten, dass Diabetes die Proliferation dieser Karzinomzellen verstärkte 
und zu erhöhtem Tumorgewicht führte, während die chronische Pankreatitis nur einen 
minimalen Einfluss auf die Pathophysiologie der Karzinome in diesem syngenen orthotopen 
Pankreaskarzinommodell hatte. Diese Daten unterstützen die Hypothese, dass Diabetes 
mellitus sowohl präkanzerogene Läsionen stimuliert und somit das Risiko erhöht, an PDA zu 
erkranken, als auch die Proliferationsrate eines etablierten PDAs verstärkt. Diese Daten sind 
auch konsistent mit der Hypothese, dass chronische Inflammation primär die frühe Phase der 
Tumorgenese beeinflusst und somit das Risiko erhöht, an PDA zu erkranken, jedoch bei 
einem etablierten Karzinom zu keiner weiteren Stimulation pathophysiologischer Vorgänge 
führt. Klinische und tierexperimentelle Studien unterstützen diese These. So reduzieren anti-
inflammatorische Medikamente die Progression präkanzerogener Läsionen, haben jedoch 
nicht automatisch therapeutisches Potenzial bei voll etablierten PDA (Furukawa  et al., 2003; 
El-Rayes et al., 2005; Funahashi et al., 2007; Mukherjee et. al., 2009).  Des Weiteren konnten 
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wir beobachten, dass Tumorzellproliferation und Tumorgröße durch Behandlung mit 
Metformin, einem traditionellen Diabetes Medikament, gehemmt wurde (Zechner et al., 2014; 
s. Anhang Teil 6). Dieses Ergebnis mit murinen Zelllinien ist konsistent zu ähnlichen 
Ergebnissen mit humanen PDA Zellen (Lonardo et al., 2013; Kisfalvi et al., 2013). In wie weit 
eine anti-tumorigene Therapie von PDA mit Metformin an Patienten sinnvoll ist, wird 
momentan mit mehreren klinischen Studien evaluiert, wobei eine endgültige Schlussfolgerung 
noch aussteht (http://clinicaltrials.gov/; Pollak, 2014; Burney et al., 2014). 
Aus den hier dargestellten Studien geht hervor, dass eine diabetische Stoffwechsellage 
einen starken Einfluss auf Erkrankungen der Bauchspeicheldrüse hat. Hyperglykämie bei 
gleichzeitiger Hypoinsulinämie wie sie bei Diabetes mellitus Typ I oder Typ 3c auftreten, 
aggraviert den Verlauf akuter und chronischer Pankreatitis. Hyperglykämie bei gleichzeitiger 
Hyperinsulinämie wie sie im Frühstadium von Diabetes mellitus Typ 2 auftritt, stimuliert PDGs, 
eine neuentdeckte anatomische Struktur im Pankreas, aus denen sich möglicher Weise 
PanINs und PDA entwickeln können. Zudem verstärkt ein dem Diabetes Typ 2 ähnliche 
metabolische Stoffwechsellage die Proliferation von Karzinomzellen in etablierten PDA. Diese 
Daten unterstützen die Hypothese, dass das klassische Konzept der Inselzell-Azinus-Achse, 
das die Kommunikation zwischen endokrinen und exokrinen Kompartiment beschreibt, eine 
besonders wichtige Bedeutung und evtl. auch klinische Relevanz bei unterschiedlichen 
Erkrankungen der Bauchspeicheldrüse hat.  
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Abstract
Aims/hypothesis It is well established that acute pancreatitis
often causes diabetes and that a high blood glucose level
associated with pancreatitis is a marker of poor prognosis.
The aim of this study was to evaluate if diabetes merely
reflects the severity of pancreatitis or whether it can also
aggravate the progression of this disease in a vicious circle.
Methods Reversible acute oedematous pancreatitis was
induced in untreated and streptozotocin-treated diabetic
mice by injection of cerulein. Progression of pancreatitis
was studied by immunohistochemistry, ELISA and various
other enzyme assays. The production of regenerating islet-
derived 3β (REG3β) was determined by western blot and
immunohistochemistry.
Results While cerulein treatment in non-diabetic mice
resulted in acute pancreatitis followed by regeneration of
the pancreas within 7 days, diabetes aggravated pancreatitis,
inhibited the regeneration of the exocrine tissue and led to
strong atrophy of the pancreas. The aggravation of pancreatitis
by diabetes was characterised by decreased production of the
anti-inflammatory protein REG3β, increased inflammation,
augmented oedema formation and increased cell death during
the acute phase of pancreatitis (p<0.05). During the
regenerative phase, diabetes augmented inflammation,
increased cell death, reduced acinar cell expansion and increased
the expansion of duct as well as interstitial cells, resulting in the
formation of tubular complexes (p<0.05). Administration of
insulin reversed the observed phenotype in diabetic mice.
Conclusions/interpretation Diabetes aggravates acute
pancreatitis and suppresses regeneration of the exocrine
tissue. Thus, diabetes is not just a concomitant phenomenon of
pancreatitis, but can have a fundamental influence on the
progression of acute pancreatitis.
Keywords Diabetes . Insulin . Pancreas regeneration .
Pancreatitis . REG3β
Abbreviations
AP Acute pancreatitis
CAE Chloroacetate esterase
REG3β Regenerating islet-derived 3β
STZ Streptozotocin
s.c. Subcutaneously
TAP Trypsinogen-activating peptide
Introduction
Acute pancreatitis (AP) is an inflammatory disease of variable
severity with an overall mortality rate of 2–3% [1]. In most
cases AP is mild and heals without any further complications.
However, 15–20% of patients develop a severe form of AP,
which is characterised by presence of organ failure and/or
local pancreatic complications such as the development of a
pseudocyst, abscess or parenchymal necrosis [1]. Most
clinical centres report mortality rates for severe AP of
5–15% and some reports even present mortality rates of
up to 25% [1, 2].
There is a well-recognised correlation between hyper-
glycaemia and acute as well as chronic pancreatitis in
patients [3, 4]. For example, temporary hyperglycaemia
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can be observed in up to 50% of patients with AP, persistent
diabetes may affect 1–15% of patients with AP, and the
prevalence of diabetes in chronic pancreatitis varies between
30% and 83%, depending on the study [5, 6]. This
correlation is usually explained by the accepted fact that
pancreatitis can cause the development of diabetes mellitus
[3]. The investigation into whether diabetes can also cause the
aggravation of pancreatitis is less tangible [3]. However,
several publications suggest that this cause-and-effect
relationship might exist. For example, patients with
diabetes have been reported to have a higher risk for
pancreatitis [7–10], and hyperglycaemia may predispose
patients with acute pancreatitis to systemic organ failure
[11]. Blood glucose level is an accurate predictor of
outcome in gallstone pancreatitis [12] and an important
criterion for the Ranson score, which is used to assess
the prognosis of AP [13]. All of these clinical studies
support the hypothesis that hyperglycaemia may aggravate
pancreatitis. However, these correlative studies cannot prove
a causal relationship.
An animal model widely used to study reversible
oedematous AP relies on the induction of pancreatic
injury with the administration of cerulein, an analogue
of the pancreatic secretagogue cholecystokinin. Administration
of a supraphysiological dose of cerulein activates trypsinogen
within acinar cells, possibly by causing a co-localisation of
digestive zymogens with lysosomal enzymes [14, 15]. After
the acute phase of pancreatitis, acinar cells respond to the tissue
injury by dedifferentiation to immature progenitor-like cells,
followed by massive proliferation and redifferentiation into
acinar cells. This leads to a recovery of the exocrine tissue
within 7 days after AP [16–18]. During the acute phase of
pancreatitis the pancreas initiates an acute emergency
programme for protecting the parenchyma. As part of this
emergency programme, the expression of genes such as Reg3β
(also known as Pap, PapI, Reg-III and Hip), is strongly upre-
gulated [19]. By using blocking antibodies, antisense oligonu-
cleotides or genetic manipulation of mice, it has been
demonstrated that regenerating islet-derived 3β (REG3β)
inhibits inflammation and protects the pancreas after cerulein-
induced pancreatitis [20–22]. Thus, REG3β is a key factor of
the acute emergency programme.
The purpose of this present study was to explore the
question of whether diabetes can influence the progression
of AP and to analyse which aspects of this disease are
affected by diabetes.
Methods
Induction of diabetes and experimental pancreatitis Male
C57BL/6 J mice were purchased from Charles River Labora-
tories (Sulzfeld, Germany) and were used at 8–12 weeks of
age with a body weight of 22–30 g or at 12months of age with
a body weight of 30–35 g. Animals were allowed access to
water and standard laboratory chow ad libitum. Diabetes was
induced by i.p. injection of 50 mg/kg streptozotocin (STZ;
Sigma-Aldrich, Steinheim, Germany) on 5 consecutive days.
Progression of diabetes was monitored with the blood glucose
meter Contour (Bayer Vital, Leverkusen, Germany). For
insulin treatment, mice received on day 15 one pellet of
insulin subcutaneously (s.c.; Linshin Canada, Toronto,
ON, Canada; release rate, 0.1 U insulin per day). For treatment
with REG3β, mice received 100 μg/kg body weight REG3β
(Dynabio, Marseille, France) i.v. 2 h before the first cerulein
injection on days 22 and 23. Pancreatitis was induced by
administration of eight i.p. injections of 50 μg/kg cerulein
(Sigma-Aldrich) at a rate of one every hour over 2 consecutive
days. All control mice were sham treated appropriately (0.9%
wt/vol. NaCl solution instead of cerulein, 50 mmol/l sodium
citrate pH 4.5 instead of STZ, wounding of the skin with a
trocar instead of insulin pellets, PBS instead of REG3β). At 2 h
before induction of pancreatitis and up to the time point of
tissue preservation all mice received drinking water containing
800 mg/l metamizol (Ratiopharm, Ulm, Germany) and
1 g/l BrdU (Sigma-Aldrich). BrdU administration had no effect
on pancreas atrophy as animals without administration of BrdU
had a similar pancreas/body weight ratio on day 30 (STZ +
cerulein with BrdU 0.0027±0.0012, n04; STZ + cerulein
without BrdU 0.0026±0.0012, n03). Animals were anaesthe-
tised with 75 mg/kg ketamine (bela-pharm, Vechta, Germany)
and 5 mg/kg xylacine (Bayer Health Care, Leverkusen,
Germany), before blood samples and organs were taken at the
indicated time points. All experiments were approved by the
local animal welfare committee and were performed in accor-
dance with the German legislation and the principles of labo-
ratory animal care (NIH publication no. 85–23, revised 1985).
Analysis of plasma Blood samples were taken 2 h after the
last cerulein injection. The activity of lipase and amylase in
plasma was analysed using the Cobas c111 spectrophotometer
(Roche Diagnostics, Mannheim, Germany). The concentra-
tion of the trypsinogen-activating peptide (TAP) in plasma
was determined by an ELISA kit for TAP (Uscn Life Science,
Wuhan, People’s Republic of China).
Histology, quantification of oedema formation, immunohis-
tochemistry and western blots Tissue was preserved 2 h
after the last cerulein injection on days 23 or 30. The tissue
was either frozen for analysis of protein concentrations or
fixed in 4% (wt/vol.) phosphate-buffered formalin for
2–3 days, embedded in paraffin and 4 μm sections were
cut. Histology was evaluated after staining the sections with
haematoxylin and eosin. To evaluate the cellular inflammatory
response, naphthol AS-D chloroacetate esterase (CAE) staining
was performed on sections. Oedema formation was quantified
Diabetologia (2012) 55:1526–1534 1527
as pancreas wet/dry weight ratio by dividing the weight of the
pancreas after drying (at 60°C for 48 h) by the weight of the
native pancreas. Cell proliferation was evaluated by immuno-
histochemistry using mouse anti-BrdU (clone Bu20a, dilution
1:50) and the Universal LSAB+ Kit/HRP kit (Dako, Hamburg,
Germany). Cell death was analysed using the ApopTag Plus
Peroxidase in situ detection kit (Millipore, Eschborn,
Germany). Immunohistochemistry for REG3β and insulin
was performed using a rat-anti-REG3β antibody (R&D
Systems, Minneapolis, MN, USA; code MAB5110, dilution
1:800) or a guinea pig-anti-insulin antibody (Abcam,
Cambridge, UK; ab7842, dilution 1:500). For quantification,
at least ten fields (each field with 300 to 650 cells using a ×40
objective) were evaluated per mouse. Acinar cells were iden-
tified by large round nuclei, granulated cytoplasm and non-
fibroblast-like appearance. Duct cells were identified by a
cobblestone-like appearance and direct proximity to a duct.
Interstitial cells were identified by interstitial localisation in
the exocrine tissue (criterion for exclusion was identification
as acinar cell, duct cell or endothelial cell). Western blots were
performed by separating 25 mg lysed tissue on 14% (wt/vol.)
SDS gels and transferring the proteins to a polyvinyldifluoride
membrane (Immobilon-P; Millipore). After blockade with 5%
(wt/vol.) milk powder, membranes were incubated overnight
at 4°C with a rat-anti-REG3β antibody (R&D Systems; code
MAB5110, dilution 1:1,000), followed by a secondary
peroxidase-linked anti-rat antibody (Santa Cruz Biotech-
nology, Santa Cruz, USA; code sc3823, dilution 1:10,000).
For analysis of β-actin production, membranes were stripped,
blocked by 2.5% (wt/vol.) BSA and incubated with mouse
anti-β-actin antibody (Sigma-Aldrich, St Louis, MO, USA;
code A5441, dilution 1:20,000) followed by peroxidase-
conjugated anti-mouse antibody (Sigma-Aldrich [USA]; code
A9044, dilution 1:60,000). Protein production was visualised
by luminol-enhanced chemiluminescence (ECL plus; GE
Healthcare, Munich, Germany) and digitalised with Chemi-
Doc XRS System (Bio-Rad Laboratories, Munich, Germany).
Signals were densitometrically assessed and corrected with
the signal intensity of β-actin (Quantity One; Bio-Rad
Laboratories).
Statistics Data are given as means and standard deviations.
The significance of data was assessed by SigmaStat3.5 software
(SigmaStat, Jandel Corporation, SanRafael, CA,USA). In cases
where the assumption of normality and homogeneity of variance
across groups was proven, differences between the groups were
calculated using the unpaired Student’s t test, including correc-
tion of the α-error according to the Bonferroni probabilities for
repeated analysis. In cases where the assumption of normality or
the homogeneity of variance across groups failed, the Mann–
Whitney rank sum test was performed, including correction of
the α-error according to the Bonferroni probabilities for
repeated analysis. The criterion for significance was p<0.05.
Results
Diabetes inhibits the remission of cerulein-induced
pancreatitis To test whether diabetes influences the pro-
gression of pancreatitis, we induced diabetes in C57BL/6 J
mice by i.p. injection of STZ (for experimental procedure
see Fig. 1a). Diabetes was characterised by average blood
glucose concentrations of 20 mmol/l on day 22 (Fig. 1b) and
a reduction in the number of insulin-producing beta cells in
the islets of Langerhans (Fig. 1c, d). STZ-treated mice lost
2.7±4.3% of their body weight, whereas non-diabetic mice
gained 4.9±3.2% body weight by day 22. We induced AP
by repeated i.p. injections of cerulein on days 22 and 23 in
diabetic (group: STZ + cerulein) as well as in non-diabetic
mice (group: cerulein) and compared them with diabetic
(group: STZ) and non-diabetic (group: sham) mice without
cerulein exposure.
On day 30 normalmorphology of the pancreas was observed
in cerulein-, STZ- and sham-treated mice (Fig. 2a [not shown
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for sham and STZ group]). At that time point, the pancreas had
regenerated after cerulein application. However, in mice
treated with STZ + cerulein only remnants of the pancreas were
visible (Fig. 2b). The pancreas/body weight ratio was reduced
in these mice by 78% when compared with sham-treated
animals (Fig. 2c). The reduction in pancreas/body weight ratio
of STZ + cerulein-treated mice was significant when compared
with the respective values of sham-, cerulein- and STZ-treated
animals (Fig. 2c).
Histological analysis of the pancreatic tissue on day 23
revealed the induction of AP in cerulein- as well as in STZ +
cerulein-treated animals (Fig. 3a,c). The pancreatic tissue of
these mice exhibited marked oedema and the typical feature
of tissue-infiltrating inflammatory cells consisting mainly of
neutrophils (Fig. 3a,c). The histology of the exocrine tissue
was normal in STZ- and sham-treated mice (Fig. 3b). On
day 30, no major histological difference was observed
between cerulein-, STZ- or sham-treated mice (Fig. 3d,e).
However, the pancreases of STZ + cerulein-treated animals
were characterised by loss of acinar cells and the appearance
of tubular complexes.
Regulation of cell expansion and cell death by diabetes To
assess the expansion of specific cell types in the diseased
pancreas, BrdU incorporation into replicating nuclei was
evaluated at the end of the acute phase on day 23 and at
the end of the regenerative phase on day 30. On day 23 no
differences in the number of BrdU-positive acinar or duct
cells between the distinct experimental groups were observed
(data not shown), but an increase in the number of BrdU-
positive interstitial cells was noticed in cerulein- and STZ +
cerulein-treated mice (17.4±4.2 and 21.3±5.7 cells per field,
respectively) when compared with control animals (sham
1.4±0.7 cells per field and STZ 2.7±0.2 cells per field). On
day 30 the number of BrdU-positive interstitial cells was
strongly increased in the STZ + cerulein-treatedmice compared
with sham-, cerulein- and STZ-treated animals (Fig. 4a–d). The
number of BrdU-positive acinar cells was significantly elevated
in cerulein-treated mice (12-fold) when compared with sham-
treated animals (Fig. 4e). However, in STZ + cerulein-treated
animals only a modest increase (2.4-fold) in the number of
BrdU-positive acinar cells was noticed when compared with
STZ-treated animals (Fig. 4e). Interestingly, significantly fewer
BrdU-positive acinar cells were also observed in the pancreas
of STZ-treated mice when compared with sham-treated
animals (Fig. 4e). The number of BrdU-positive duct cells in
the pancreas was highly increased in the STZ + cerulein-treated
mice when compared with sham-, STZ- and cerulein-treated
animals (Fig. 4a,b,f). In order to evaluate the extent of cell
death during pancreatitis, we detected double-stranded DNA
breaks on histological sections. On days 23 and 30, cells with
DNA breaks were primarily observed in cerulein- and STZ +
cerulein-treated mice (Fig. 5a–d). At both time points STZ +
cerulein-treated animals had a significant increase in the
number of cells with DNA breaks when compared with
sham-, cerulein- or STZ-treated animals (Fig. 5e,f).
Diabetes affects pancreatic inflammation As cerulein-
induced pancreatitis is characterised by infiltration of granu-
locytes, which strongly express CAE, we evaluated the
number of tissue-infiltrating CAE-positive cells in the
pancreas. On day 23, almost no CAE-positive cells were
observed in STZ- and sham-treated mice, while after treatment
with cerulein an increase in the number of CAE-positive infil-
trated cells was observed (electronic supplementary material
[ESM] Fig. 1a,b; Fig. 6a). An even stronger increase in the
number of CAE-positive cells was observed after treatment
with STZ + cerulein (ESM Fig. 1c; Fig. 6a). To compare the
infiltration of immune cells to the magnitude of tissue oedema,
we analysed the pancreas wet/dry weight ratio. In sham-treated
mice the wet/dry weight ratio was 3.51±0.04. After treatment
with cerulein a significant increase in the pancreas wet/dry
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weight ratio to 4.58±0.03 was observed (Fig. 6b). Treatment
with STZ + cerulein resulted in a significant rise in the wet/dry
weight ratio to 10.31±0.19 (Fig. 6b).
On day 30 almost no CAE-positive infiltrating cells were
observed in STZ-, cerulein- or sham-treated animals while
in STZ + cerulein-treated animals a considerable number of
CAE-positive cells were observed (ESM Fig. 1d–f; Fig. 6c).
Activation of trypsinogen and suppression of REG3β
production As inappropriate intracellular proteolytic activa-
tion of trypsinogen to trypsin has been considered to be the
pathological event that initiates pancreatitis [23], we evaluated
whether diabetes modulates trypsinogen activation. For this
purpose we measured the concentration of TAP in the plasma
2 h after the last cerulein injection. After treatment with cerulein
or STZ + cerulein a twofold increase in the concentration of
TAP was observed (Fig. 7a). Importantly, no difference
in the concentration of TAP was observed between
cerulein- and STZ + cerulein-treated mice (Fig. 7a).
We also analysed lipase activity and amylase activity
in the plasma. Lipase activity in the plasma was induced
eightfold in cerulein-treated mice compared with sham-
treated animals and 29-fold in STZ + cerulein-treated mice
compared with STZ-treated animals (Fig. 7b). Similarly, the
activity of amylase was induced sixfold in cerulein-treated
mice compared with sham-treated animals and 13-fold
in STZ + cerulein-treated mice compared with STZ-treated
animals (Fig. 7c).
In order to evaluate, whether the production of REG3β,
an important protein induced by the emergency programme
during pancreatitis, is altered in diabetic mice, we analysed
the production of this protein by immunohistochemistry.
REG3β production was not detected in the acinar cells of
sham- or STZ-treated mice, but was produced in abundance
2 h after the last cerulein treatment in diabetic as well as
non-diabetic mice (Fig. 7d–f; not shown for sham group). In
order to quantify REG3β, we analysed relative protein con-
centrations by western blot. After cerulein administration
STZ-treated animals showed a significantly lowered level
of REG3β production when compared with cerulein-treated
non-diabetic animals (Fig. 7g, h). We also evaluated whether
administration of REG3β can inhibit the inflammation during
pancreatitis. On day 23, we observed a small 5.3% decrease
(not significant) in the number of CAE-positive cells in STZ+
REG3β+cerulein-treated mice when compared with STZ +
cerulein-treated animals (data not shown).
Progression of pancreatitis in insulin-treated and aged
mice In order to evaluate whether the observed phenotype
is reversible by treating diabetes with insulin, we implanted
insulin-containing pellets s.c. in STZ-treated mice on
day 15. Insulin treatment reduced the glucose concentration
by day 22 (Fig. 8a). After induction of pancreatitis we
observed on day 30 that STZ + insulin + cerulein-treated
mice had an increased pancreas/body weight ratio, reduced
cell death, reduced expansion of interstitial cells as well as
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duct cells and enhanced expansion of acinar cells (Fig. 8b–f)
when compared with STZ + cerulein-treated mice. In order
to evaluate whether diabetes has a similar effect in aged
mice, we compared the pancreases of STZ- and STZ +
cerulein-treated 12-month-old mice. Also in aged mice,
diabetes reduced acinar cell, but increased interstitial cell
as well as duct cell expansion, increased the number of
CAE-positive cells, reduced the pancreas/body weight ratio
and increased cell death on day 30 (ESM Fig. 2a–f).
Discussion
In order to test the hypothesis that diabetes is not only a
concomitant phenomenon of AP, but can also aggravate this
disease, we compared the progression of pancreatitis after
induction of pancreatitis in non-diabetic and diabetic mice.
The following observations documented that experimental
diabetes caused an aggravation of cerulein-induced AP.
Compared with non-diabetic mice, diabetic mice displayed:
(1) an enhanced and extended inflammatory response; (2)
increased local oedema formation; (3) enhanced cell death;
(4) reduced acinar cell expansion but increased duct cell as
well as interstitial cell expansion; (5) reduced production of
REG3β; and (6) increased activity of lipase and amylase in
blood plasma. The increased cell death and inhibited regen-
eration of acinar cells resulted in almost complete atrophy of
the pancreas. Administration of insulin lowered the blood
glucose concentration and inhibited the observed aggravation
of pancreatitis by diabetes. This suggests that the diabetic
metabolic state rather than non-specific cytotoxicity of
administered compounds aggravates pancreatitis. The
observed protective effect of insulin might also explain
why evolutionary pressure caused the dispersion of the endo-
crine islets of Langerhans within a predominantly exocrine
organ [24]. This so-called islet–acinar axis might not only be
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Fig. 8 Influence of insulin
administration on pancreatitis
induced atrophy. Insulin
administration reduces blood
glucose concentration (a) by
day 22. Comparison of STZ +
cerulein-treated (n05) with
STZ + insulin + cerulein-treated
(n06) mice on day 30 demon-
strates that insulin increases
pancreas/body weight ratio (b),
reduces cell death (c), reduces
the number of BrdU-positive
interstitial cells (d), increases
the number of BrdU-positive
acinar cells (e) and decreases
the number of BrdU-positive
duct cells (f). Values denote
mean±SD. Significant differences
are marked (*). Cer, cerulein; Ins,
insulin
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relevant for normal physiology of exocrine tissue, but might
be especially relevant for distinct pathologies such as
pancreatitis.
AP is thought to be caused by the intracellular activation
of trypsinogen [23]. However, in our study diabetes had no
influence on the concentration of TAP in the plasma of mice
2 h after the last cerulein injection, suggesting that diabetes
might influence downstream mechanisms of pancreatitis
rather than the activation of trypsinogen. One of these
downstream mechanisms might be the induction of the acute
emergency programme. REG3β is part of the acute emer-
gency programme for protecting the pancreas and has been
shown to inhibit inflammation during pancreatitis [20–22].
We demonstrate that REG3β production is significantly
suppressed in diabetic mice during pancreatitis. This finding
is surprising, as REG3β production usually correlates with
the severity of pancreatitis in animal models as well as in
patients [25, 26]. The suppression of REG3β production
suggests that the inhibitory mechanism of diabetes on
REG3β production overwhelms the stimulatory mechanisms
of aggravated pancreatitis. However, we observed only a small
non-significant repression of inflammation after administration
of REG3β. These data suggest that diabetes significantly alters
the induction of the emergency programme during pancreatitis,
but that several additional factors in addition to reduced
REG3β production might contribute to the aggravation of
pancreatitis in diabetic mice. We did not observe an obvious
increase in REG3β protein in STZ-treated mice when
compared with sham-treated animals, whereas other groups
could demonstrate an increase in Reg3βRNA level in diabetic
animals [27, 28]. These seemingly conflicting results could be
explained by assuming that the detection limit for Reg3βRNA
might be lower than the detection limit for REG3β protein or
that results from RNA analysis do not always correlate with
the actual protein content.
Differences between diabetic and non-diabetic mice were
first observed 2 h after the last cerulein injection and included
reduced production of REG3β, increased activity of lipase and
amylase in blood plasma, enhanced inflammatory response,
increased local oedema formation and increased cell death.
Other differences such as reduced acinar cell expansion were
observed on day 30, but not on day 23. This observation is
consistent with data describing that the main cell expansion of
acinar cells occurs during the regenerative, but not the acute,
phase of pancreatitis [16, 17]. Interestingly, a significant reduc-
tion in BrdU-positive acinar cells was observed in diabetic
mice even in the absence of pancreatitis when comparing
diabetic mice with sham-treated animals. These data suggest
that diabetes might directly inhibit the expansion of acinar cells
independent of pancreatitis. In addition, we observed that
STZ + cerulein treatment influenced cell expansion in a cell-
type-specific manner. Diabetes inhibited the expansion
of acinar cells, whereas it induced the expansion of interstitial
cells and duct cells after pancreatitis. This stimulatory
effect on the expansion of these cells might, however,
constitute the response of the tissue to increased tissue
damage in diabetic mice.
The distinct proliferative behaviour of acinar and duct
cells in response to diabetes may lead to the observed
formation of tubular complexes in diabetic mice. Though
the significance of tubular complexes is controversial, they
have been proposed to be early cancer precursors [29, 30]
and are formed by transdifferentiation of acinar cells to duct
cells, as well as increased proliferation of duct cells [31].
Possibly, the increased formation of tubular complexes in
diabetic mice after pancreatitis may provide an explanation
for the observation that diabetes and chronic pancreatitis are
major risk factors for pancreatic cancer [32–35].
Up to 50% of patients with AP have an elevated blood sugar
level [3, 5, 6]. In these patients hyperglycaemia may be caused
by decreased insulin secretion, parenteral nutritional therapy,
increased gluconeogenesis and decreased glucose use [3].
These patients, however, are also susceptible to hypoglycaemia,
resulting in conservative insulin therapy at intensive care units
[3]. During the last 10 years an intensified insulin therapy for
critically ill patients has been a major issue of discussion. An
intensified insulin therapy has been found to be of benefit or of
no benefit to patients, depending on the clinical study [36–38].
Possibly this discrepancy may be resolved by the assumption
that an intensified insulin therapy is beneficial to certain subsets
of patients, whereas in other subsets of critically ill patients the
risk of hypoglycaemia will outweigh beneficial effects. Thus, it
is essential to understand whether diabetes can aggravate dis-
tinct diseases such as AP or whether diabetes is just a concom-
itant phenomenon of specific diseases. Additional preclinical as
well as clinical studies might, therefore, be expedient to provide
evidence for the decision on whether repetitive blood glucose
measurements or technological advances such as continuous
glucose monitoring systems followed by precise blood glucose
control may improve the survival of patients with severe AP.
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Abstract: Since hyperglycemia aggravates acute pancreatitis and also activates the receptor for advanced glyca-
tion endproducts (RAGE) in other organs, we explored if RAGE is expressed in the pancreas and if its expression is 
regulated during acute pancreatitis and hyperglycemia. Acute pancreatitis was induced by cerulein in untreated and 
streptozotocin treated diabetic mice. Expression of RAGE was analyzed by Western blot and immunohistochemistry. 
To evaluate signal transduction the phosphorylation of ERK1/ERK2 was assessed by Western blot and the progres-
sion of acute pancreatitis was monitored by evaluation of lipase activity and the pancreas wet to dry weight ratio. 
RAGE is mainly expressed by acinar as well as interstitial cells in the pancreas. During acute pancreatitis infiltrat-
ing inflammatory cells also express RAGE. Using two distinct anti-RAGE antibodies six RAGE proteins with diverse 
molecular weight are detected in the pancreas, whereas just three distinct RAGE proteins are detected in the lung. 
Hyperglycemia, which aggravates acute pancreatitis, significantly reduces the production of two RAGE proteins in 
the inflamed pancreas.
Keywords: Receptor for advanced glycation endproducts (RAGE) isoforms, soluble RAGE, pancreatitis, hyperglyce-
mia, inflammation, ERK1/ERK2 phosphorylation
Introduction
Acute as well as chronic pancreatitis often cor-
relates with hyperglycemia in patients [1-4]. 
This correlation may be explained by two causal 
relationships. On the one hand it is well accept-
ed that pancreatitis can cause the develop-
ment of diabetes mellitus [2]. On the other 
hand several publications suggest that diabe-
tes causes also the aggravation of pancreatitis 
[2]. For example, hyperglycemia may predis-
pose patients with acute pancreatitis to sys-
temic organ failure and patients with diabetes 
have a higher risk for pancreatitis [5-9]. 
Moreover, blood glucose level is an important 
criterion for assessing the prognosis of acute 
pancreatitis by the Ranson score and is also an 
accurate predictor of the outcome in gallstone 
pancreatitis [10, 11]. In addition, experiments 
using an animal model for reversible edema-
tous acute pancreatitis have demonstrated 
that hyperglycemia indeed aggravates pancrea- 
titis by enhancing inflammation and inducing 
cell death, which results in ample atrophy of the 
pancreas [12].
A membrane bound receptor, which has been 
implicated in regulating inflammation, is the 
receptor for advanced glycation end products 
(RAGE) [13, 14]. This receptor is activated by a 
diverse group of molecules such as S100 pro-
teins, high mobility group box-1 (HMGB1) pro-
tein, lipopolysaccharide (LPS) or advanced gly-
cation end products (AGEs) [15]. The association 
of these ligands with N-terminal domains of 
RAGE results in the induction of pro-inflamma-
tory intracellular signaling cascades, such as 
the ERK1/ERK2 MAPK or the NF-κB signaling 
pathway [13]. Membrane bound RAGE has, 
therefore, a pro-inflammatory function during 
various pathologies such as rheumatoid arthri-
tis, atherosclerosis, septic shock and endotox-
emia [16-19]. Some truncated isoforms of 
RAGE, however, do not contain the membrane 
binding domain, but span the N-terminal extra-
cellular ligand-binding domain. These isoforms 
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are not membrane bound, but soluble, and 
have been proposed to have anti-inflammatory 
function by acting as a decoy for RAGE ligands 
[20]. Such soluble RAGE isoforms are produced 
by either proteolytic cleavage of the membrane 
bound RAGE or alternative splicing of the RAGE 
pre-mRNA [21-25]. Indeed, administration of 
soluble RAGE has been demonstrated to inhibit 
various diseases, such as atherosclerosis, 
ischemia/reperfusion injury and autoimmune 
diabetes [17, 26-28]. Thus, different forms of 
RAGE have pro- and anti-inflammatory func- 
tions.
The aim of the present study was to assess i) if 
RAGE is expressed in the pancreas, ii) if the 
expression is altered during acute pancreatitis 
and iii) if the expression correlates with hyper-
glycemia induced aggravation of acute pancr- 
eatitis.
Materials and methods
Animals
8-12 weeks old C57BL/6J mice were grouped 
into 4 cohorts, which were either sham (Sham), 
cerulein (Cer), streptozotocin (STZ) or strepto-
zotocin plus cerulein treated (STZ+Cer). Ex- 
periments were performed under analgesia as 
described previously [12]. In brief, diabetes 
was induced in two cohorts (STZ, STZ+Cer) by 
intraperitoneal (i.p.) injection of 50 mg/kg 
streptozotocin (Sigma-Aldrich, St Louis, MO, 
USA) on 5 consecutive days and diabetes was 
monitored with the blood glucose meter 
Contour (Bayer Vital, Leverkusen, Germany) for 
3 weeks before pancreatitis was induced in two 
cohorts (Cer, STZ+Cer). Acute pancreatitis was 
induced either by administration of six i.p. injec-
tions of 50 μg/kg cerulein (Sigma-Aldrich) at a 
rate of one every hour (analysis: 5.5 hours after 
the first cerulein injection) or by administration 
of eight i.p. injections of 50 μg/kg cerulein at a 
rate of one every hour over 2 consecutive days 
(analysis: 33 hours after the first cerulein injec-
tion). All control mice were sham treated appro-
priately (0.9% wt/vol. saline solution instead of 
cerulein, 50 mmol/l sodium citrate pH 4.5 
instead of STZ).
Analysis of plasma and tissue 
Oedema formation was quantified as pancreas 
wet to dry weight ratio by dividing the weight of 
the pancreas after drying (for 48 h at 60°C) by 
the weight of the native pancreas. Blood sam-
ples were taken at the indicated time points 
after the first cerulein injection. The activity of 
lipase and amylase in plasma was analyzed 
using the Cobas c111 spectrophotometer 
(Roche Diagnostics, Mannheim, Germany). 
Pancreas and lung tissue for Western blots and 
immunohistochemistry was preserved at the 
indicated time points after the first cerulein 
injection and processed as described previous-
ly [12]. Western blots were performed by sepa-
rating 10 mg pancreas lysate or 0.4 mg lung 
lysate on 12% (wt/vol.) SDS gels. After transfer-
ring the proteins to a polyvinyldifluoride mem-
brane (Immobilon-P; Millipore) the membrane 
was blocked with 2.5% (wt/vol.) bovine serum 
albumin (BSA) and incubated overnight at 4°C 
with primary antibodies. As primary antibodies 
a goat anti-RAGE antibody raised against an 
epitope at the N-terminus of RAGE (Santa Cruz 
Biotechnology, Santa Cruz, USA; code sc8230, 
1:1250), a goat anti-RAGE antibody raised 
against Gln24 to Ala342 of mouse RAGE (R&D 
Systems, Wiesbaden, Germany, code AF1179, 
1:500), or a rabbit anti-phospho-ERK1/2(T202/
Y204)/ERK2(T185/Y187) antibody (R&D Sys- 
tems, code MAB1018, 1:1000) were used. 
After washing, the membrane was incubated 
for 2 hours at room temperature with a second-
ary peroxidase-linked anti-goat-antibody (Santa 
Cruz Biotechnology, code sc2020, 1:15000) or 
peroxidase-linked anti-rabbit-antibody (Cell 
Signaling, Boston, USA, code 7074, 1:5000). 
For analysis of β-tubulin or ERK1/ERK2 produc-
tion, membranes were stripped, blocked by 
2.5% (wt/vol.) BSA and incubated with a rabbit 
anti-β-tubulin antibody (Santa Cruz Biotech- 
nology, code sc9104, 1:500) or a mouse anti-
ERK1/ERK2 antibody (R&D Systems, code 
MAB15761, 1:500) followed by incubation of 
peroxidase conjugated anti-rabbit antibody 
(Cell Signaling, code 7074, 1:15000) or a per-
oxidase conjugated anti-mouse antibody (Sig- 
ma-Aldrich, code A9044, 1:20000). Proteins 
were detected by luminol-enhanced chemilumi-
nescence and quantified by densitometry. The 
signal intensities of phospho-ERK1/ERK2 were 
corrected with the corresponding signal intensi-
ties of ERK1/ERK2. The signal intensities of all 
other proteins were corrected with the corre-
sponding signal intensities of β-tubulin. 
Immunohistochemistry for RAGE was per-
formed using a goat anti-RAGE antibody (Santa 
Cruz Biotechnology, code sc8230, 1:1000) and 
peroxidase conjugated donkey-anti-goat anti-
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body (Santa Cruz Biotechnology, code sc2020, 
1:100).
Statistics
Data are presented as box plots indicating the 
median, the interquartile range in form of a box, 
and the 10th and 90th percentiles as whiskers. 
Graphs were made by using SigmaPlot soft-
ware version 12.0. The significance of data was 
assessed by SigmaStat software version 3.5 
(SigmaStat, Jandel Corporation, San Rafael, 
CA, USA). Differences between the groups were 
calculated using Kruskal-Wallis One Way An- 
alysis of Variance on Ranks with the pairwise 
multiple comparison procedure as suggested 
by the software and indicated in the figure leg-
ends. The criterion for significance was p<0.05.
Results
RAGE expression in the native pancreas
In order to compare RAGE expression in the 
pancreas to its well characterized expression in 
lung, the tissue lysates of both native organs 
were analyzed by Western blot using two dis-
tinct anti-RAGE antibodies (Figure 1A). In lung 
three RAGE proteins, the membrane bound 
X-RAGE, RAGE and a soluble sRAGE, were 
detected in agreement with previously pub-
lished data [24, 29]. In pancreas, however, six 
RAGE proteins were consistently detected by 
both antibodies (Figure 1A). Experiments leav-
ing the pancreas up to 20 minutes at room tem-
perature before lysing the tissue confirmed that 
the RAGE proteins with lower molecular weight 
were not degradation products of the RAGE 
proteins with higher molecular weight (data not 
shown). Immunohistochemistry revealed strong 
RAGE expression in acinar and interstitial cells 
as well as weak expression in the islets of 
Langerhans (Figure 1B-E).
Regulation of RAGE expression by hyperglyce-
mia and pancreatitis
In order to assess if the expression of any of 
the six RAGE proteins (RAGE 1-6) is altered by 
hyperglycemia or acute pancreatitis, four dis-
tinct cohorts of mice were sham, cerulein, 
streptozotocin or streptozotocin plus cerulein 
treated. Repetitive cerulein injections induced 
acute pancreatitis 33 hours after the first ceru-
lein administration, as characterized by incr- 
eased lipase activity in the blood (Sham: 
31/26-43, cerulein: 657/512-689, STZ: 27/25-
31, STZ+cerulein: 1636/1076-1795, median/
interquartile range in units/l). Consistent with 
previously published data, STZ+cerulein treat-
ment caused higher lipase activity compared to 
cerulein-treated mice [12]. In mice treated with 
STZ three weeks before tissue asservation, the 
blood glucose concentration was strongly 
increased at the time point when pancreatitis 
was induced (Sham: 6.7/6.1-7.2, cerulein: 
6.6/6.0-7.3, STZ: 31.5/28.2-33.3, STZ+ceru- 
lein: 29.0/19.2-32.6, median/interquartile 
range in mmol/l). The expression of RAGE 1 
was modestly reduced by application of STZ, 
Figure 1. Detection of RAGE proteins in murine lung 
and pancreas. Western blots using two distinct anti-
RAGE antibodies, R&D AF1179 and sc-8230, detect-
ed three and six RAGE proteins in murine lung and 
pancreas, respectively (A). Immunohistochemistry 
on pancreas tissue using the sc-8230 anti-RAGE an-
tibody detected RAGE in acinar cells (B), in the islets 
of Langerhans (C), and in interstitial cells (D), while 
no staining was observed in the negative control 
when the primary antibody was omitted (E). Bar=20 
micrometer.
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cerulein or the application of STZ+cerulein 
compared to sham-treated mice (Figure 
2A-C). In contrast, the expression of RAGE 
2-6 was reduced mainly by application of 
STZ+cerulein (Figure 2D-H). Especially 
RAGE 5 and 6 were reduced significantly 
by application of STZ+cerulein compared 
to cerulein-treated mice (Figure 2G and 
2H). Evaluation of the pancreatic tissue by 
immunohistochemistry suggests a reduc-
tion of RAGE expression in acinar cells 
during inflammation (Figure 3A-D). 
However, at the same time point infiltrat-
ing inflammatory cells express RAGE 
strongly (Figure 3A-D). In summary, these 
data correlate the reduced expression of 
RAGE 5 and 6 with the previously pub-
lished aggravation of acute pancreatitis 
caused by hyperglycemia [12].
Time course of ERK1/ERK2 activation 
and RAGE expression
In order to evaluate at which time point a 
classical RAGE induced signal transduc-
tion pathway, the ERK1/ERK2 MAPK path-
way, is activated during acute pancreati-
tis, we evaluated the phosphorylation of 
ERK1/ERK2 on various time points during 
the first and second day of repetitive ceru-
lein administration. Cerulein induces the 
phosphorylation of ERK1/ERK2 within 1.5 
hours after the first cerulein injection and 
the phosphorylation reaches its maximum 
at 5.5 hours after the first cerulein admin-
istration (Figure 4A-C). At 5.5 as well as 
10 hours after the first cerulein injection 
the amount of RAGE protein 5 and 6 was 
Figure 2. Influence of hyperglycemia and pan-
creatitis on RAGE proteins in the pancreas 33 
hours after the first cerulein administration. 
Pancreas of control (sham), cerulein (Cer), 
streptozotocin (STZ) or streptozotocin plus ce-
rulein (STZ+Cer) treated mice were analyzed 
by Western blots using the sc-8230 anti-RAGE 
antibody (A) and an anti-β-tubulin antibody 
as control (B). Densitometry of Western blots 
compared the expression of RAGE 1-6 (C-H) 
and revealed a significant reduction of RAGE 5 
and 6 in STZ+cerulein treated mice (G and H). 
Values denote median and interquartile range. 
*p≤0.038 versus cerulein treated mice using 
Kruskal-Wallis One Way Analysis of Variance on 
Ranks followed by Tukey Test for all pairwise 
comparisons.
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moderately increased (Figure 4D and 4E). 
These data suggest that phosphorylation of 
ERK1/ERK2 might be studied best 5.5 hours 
after the first cerulein injection. 
ERK1/ERK2 activation and RAGE expression 
during the early phase of acute pancreatitis 
In order to assess, if the ERK1/ERK2 MAPK 
signal transduction pathway is altered by hyper-
glycemia or pancreatitis 5.5 hours after the 
first cerulein injection, the phosphorylation of 
ERK1/ERK2 was assessed in sham, cerulein, 
STZ and STZ+cerulein-treated animals 5.5 
hours after the first cerulein administration. 
Both cerulein as well as STZ+cerulein treat-
ment caused strong phosphorylation of ERK1/
ERK2 (Figure 5A and 5B). However, STZ+ce- 
rulein administration did not lead to a signifi-
cantly altered phosphorylation of ERK1/ERK2 
compared to cerulein-treated mice (Figure 5C). 
The expression of RAGE 5 and 6 was also 
almost unchanged when comparing the 
STZ+cerulein with cerulein-treated mice (RAGE 
5: cerulein 1.4/0.9-2.1, STZ+cerulein 1.3/0.9-
1.3, RAGE 6: cerulein 1.4/1.2-1.7, STZ+cerulein 
1.3/1.1-1.7, median/interquartile range in rela-
tive expression intensity). At this early time 
point cerulein as well as STZ+cerulein applica-
tion caused increased wet to dry weight ratio of 
the pancreas (Figure 5D). Furthermore lipase 
as well as amylase activity were increased in 
the blood plasma compared to sham-treated 
mice (Figure 5E and 5F). However, STZ+cerulein 
administration, compared to cerulein-treated 
mice, did neither lead to a significantly altered 
wet to dry weight ratio of the pancreas nor to 
significantly altered lipase or amylase activities 
at this early time point (Figure 5D-F). Hyperg- 
lycemia, therefore, has no obvious effect on the 
early phase of acute pancreatitis in contrast to 
strong aggravation of pancreatitis at a later 
time point [12].
Figure 3. Influence of hyperglycemia and pancreatitis 
on RAGE in the pancreas 33 hours after the first ce-
rulein administration. Pancreas of sham (A), cerulein 
(B), streptozotocin (C) or streptozotocin plus cerulein 
(D) treated mice were analyzed by immunohisto-
chemistry using the sc-8230 anti-RAGE antibody. In-
filtrating inflammatory cells produce RAGE indicated 
by arrows in B and D. Bar=20 μm.
Figure 4. Time course of ERK1/ERK2 activation and 
RAGE expression during repetitive cerulein admin-
istration. The phosphorylation of ERK1/ERK2 was 
analyzed by Western blots (arrowheads, A) and com-
pared to ERK1/ERK2 expression (arrows, B) at the 
indicated time points after the first cerulein adminis-
tration. The phosphorylation intensity of ERK1/ERK2 
reveals a maximum of phosphorylation at 5.5 hours 
after the first cerulein administration (C). No obvious 
effect on the expression level of any of the six RAGE 
proteins was observed 5.5 hours after the first ceru-
lein administration (D) compared to β-tubulin expres-
sion (E).
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Discussion
The evaluation of RAGE expression in the pan-
creas demonstrates that i) six RAGE proteins 
with distinct apparent molecular weight can be 
detected in the pancreas (Figures 1A and 2A), 
ii) the expression of two RAGE proteins is sig-
nificantly reduced in hyperglycemic mice during 
the late phase of acute pancreatitis (Figure 2A) 
and iii) that this reduction correlates with an 
aggravation of acute pancreatitis [12]. 
For the detection of the six RAGE proteins in 
pancreas, two different RAGE antibodies were 
used to control for possible unspecific binding 
of an antibody to other proteins. These two 
anti-RAGE antibodies were either raised against 
a peptide mapping directly at the N-terminus of 
RAGE [29] or were raised against Gln24 to 
Ala342 of RAGE. Since the N-terminal Ig 
domain, called V domain (amino acid 34-110 of 
mouse RAGE), is the primary binding site for 
most ligands, we reason that all six detected 
RAGE proteins in the pancreas may bind RAGE 
ligands [30]. RAGE 2 has a similar molecular 
weight as the membrane bound RAGE isoform 
in the lung and might therefore be a membrane 
bound full length RAGE protein [24, 29]. RAGE 
proteins with lower molecular weight, such as 
RAGE 4, 5 and 6, contain the N-terminus of 
RAGE, but probably not the entire C-terminal 
domain. Since the membrane binding domain 
of RAGE is encoded by amino acids 341-361 
close to the C-terminus [30], such proteins 
Figure 5. Influence of hyperglycemia and cerulein administration on RAGE proteins and on parameters of pancre-
atitis 5.5 hours after the first cerulein administration. Pancreas and blood plasma of control (sham), cerulein (Cer), 
streptozotocin (STZ) or streptozotocin plus cerulein (STZ+Cer) treated mice were analyzed. The phosphorylation of 
ERK1/ERK2 (arrowheads, A) was compared to ERK1/ERK2 expression (arrows, B) by Western blots. The quantifica-
tion by densitometry reveals increased phosphorylation of ERK1/ERK2 after cerulein as well as STZ+cerulein treat-
ment (C). Pancreatitis was quantified by pancreas wet to dry weight ratio (D) and lipase (E) and amylase (F) activity 
in blood plasma. Box plots indicate the median, the interquartile range in the form of a box and the 10th and 90th 
percentiles as whiskers. *p≤0.01 versus sham treated mice and #p≤0.003 versus STZ treated mice using Kruskal-
Wallis One Way Analysis of Variance on Ranks followed by Tukey Test (C) or Dunn’s Method (D-F) for all pairwise 
comparisons.
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would not be membrane bound, but soluble. 
Such proteins have been described previously 
in the literature and are generated by a shed-
dase which proteolytically processes full length 
RAGE or by alternative splicing of the pre-mRNA 
of RAGE [20-25]. Soluble RAGE (sRAGE) has 
been demonstrated to inhibit inflammation in 
several pathological processes such as athero-
sclerosis, ischemia/reperfusion injury and auto- 
immune diabetes by serving as decoy receptor 
for RAGE ligands [17, 26-28]. In pancreas we do 
observe a RAGE protein with very similar molec-
ular weight to sRAGE (RAGE 4). Its expression is 
reduced after STZ+cerulein application com-
pared to cerulein treatment (Figure 2F). Due to 
the anti-proliferative function of sRAGE in other 
distinct diseases, the reduced expression of 
RAGE 4 in hyperglycemic mice could be partial-
ly responsible for the observed aggravation of 
acute pancreatitis by hyperglycemia [12]. 
Interestingly, we also observe two additional 
RAGE proteins with approximate molecular 
weight of 32 (RAGE 5) and 27 kDa (RAGE 6). 
The expression of these small RAGE proteins, is 
significantly reduced after STZ+cerulein appli-
cation compared to cerulein treatment (Figure 
2G and 2H). In analogy to sRAGE, the reduced 
expression of RAGE 5 and RAGE 6 in hypergly-
cemic mice could be partially responsible for 
the observed aggravation of acute pancreatitis 
by hyperglycemia [12]. RAGE 5 and RAGE 6 
might act as decoy receptor for HMGB1, LPS or 
S100 proteins which stimulate inflammation by 
binding to receptors such as TLR4 or mem-
brane bound RAGE [13, 31]. Since RAGE has 
been described to be alternatively spliced, pro-
teolytically processed and N-glycosylated, any 
of these processes or even a combination of 
them might result in the six RAGE proteins in 
the pancreas [20, 21, 23-25, 29, 32]. It has 
been reported that PNGaseF treated lung 
extract resulted in deglycosylated RAGE pro-
teins with an apparent molecular weight well 
above 40 kDa [29]. Interestingly, RAGE 5 and 6 
have an apparent molecular weight well below 
35 kDa. Thus it is unlikely that a lack of 
N-glycosylation alone can explain the low 
molecular weights of RAGE 5 and RAGE 6. It is 
more likely that these short proteins are gener-
ated by alternative splicing or proteolytic pro-
cessing of RAGE.
The aggravation of acute pancreatitis by hyper-
glycemia was observed at late time points such 
as 33 hours after the first cerulein administra-
tion and during the regeneration phase of the 
pancreas [12], but was not observed during the 
early phase of pancreatitis, 5.5 hours after the 
first cerulein injection (Figure 5D-F). This sug-
gests, that hyperglycemia does not influence 
early events during pancreatitis, but might have 
a major influence on the perpetuation of inflam-
mation. Since RAGE has also been suggested 
to regulate the perpetuation of inflammation in 
other context [33], it is likely that it has a similar 
function during pancreatitis. Hyperglycemia 
might therefore aggravate pancreatitis by 
increasing the concentration of AGEs or other 
RAGE ligands and by reducing the expression of 
soluble RAGE proteins with anti-inflammatory 
functions.
Based on the correlation of RAGE 5 and RAGE 
6 production in the pancreas and the progres-
sion of pancreatitis, additional research could 
focus on the following questions: i) Can the 
RAGE 5 and RAGE 6 proteins be isolated and 
the amino acid sequences be defined? ii) Do 
these two RAGE proteins inhibit inflammation? 
iii) Are these RAGE proteins more or less potent 
than sRAGE in inhibiting inflammation? And iv) 
does RAGE influence pancreatitis?
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SUMMARY
Acute pancreatitis (AP) can lead to a systemic inflammatory response that often
results in acute lung injury and single or multiple organ failure. In a previous study
we demonstrated that diabetes aggravates the local pathophysiological process
during AP. In this study we explore, if diabetes also increases pancreatitis induced
systemic inflammation and causes lung injury. Acute pancreatitis was induced in
untreated and streptozotocin-treated diabetic mice by injection of cerulein. Systemic
inflammation was studied by IL-6 ELISA in blood plasma and white blood cell
count. Lung inflammation and lung injury were quantified by chloroacetate esterase
staining, evaluation of the alveolar cellularity index and cleaved caspase-3 immuno-
histochemistry. In normoglycaemic mice AP increased the IL-6 concentration in
plasma and caused lymphocytopenia. Diabetes significantly increased the IL-6 con-
centration in plasma and further reduced the number of lymphocytes during AP,
whereas diabetes had little effect on these parameters in the absence of pancreatitis.
However, diabetes only marginally increased lung inflammation and did not lead to
cell death of the lung epithelium during AP. We conclude that diabetes increases
parameters of systemic inflammation during AP, but that this increase is insufficient
to cause lung injury.
Keywords
acute lung injury, chloroacetate esterase staining, cleaved caspase-3, sepsis, systemic
inflammatory response syndrome
About 15%–20% of patients with acute pancreatitis (AP)
develop severe symptoms, such as pancreatic parenchymal
necrosis, a systemic inflammatory response and concomi-
tant single or multiple organ failure (Forsmark & Baillie
2007). The AP-induced inflammatory response often causes
acute lung injury (ALI) with a mortality rate of up to 40%
(Zhou et al. 2010). This is often associated with lymphope-
nia and an increase in the concentration of the pro-inflam-
matory cytokine IL-6 in the blood (Takeyama et al. 2000;
Gregoric et al. 2010). IL-6 is not only of prognostic value,
but has also been demonstrated to be an essential mediator
of pancreatitis-associated lung injury (Zhang et al. 2013).
The pro-inflammatory milieu during AP leads to activation
and infiltration of neutrophil granulocytes in the lung and
to an increase in the alveolar cellularity index (Guice et al.
1989; Frossard et al. 1999; Pastor et al. 2006; Tascilar
et al. 2007). Pulmonary inflammation can cause lung
injury, which is often characterized by apoptosis of lung
epithelial cells (Yuan et al. 2000; Nakamura et al. 2003).
Although several proteins, such as the cytokine induced
neutrophil chemoattractant, the CD40 ligand or the toll-
like receptor 4, have been implicated in the pathophysio-
logical process of AP-induced ALI, underlying mechanisms
and contributing parameters of this process are still not
well understood (Bhatia et al. 2000; Frossard et al. 2001;
Sharif et al. 2009; Zhou et al. 2010).
One parameter that has been described to aggravate AP is
diabetes. Several correlative studies in patients have suggested
that diabetes leads to a higher risk for pancreatitis (Seicean
et al. 2006; Noel et al. 2009; Girman et al. 2010; Xue et al.
2012) and that hyperglycaemia may predispose patients with
AP to systemic organ failure (Mentula et al. 2008). In addi-
© 2014 The Authors.
International Journal of Experimental Pathology © 2014 International Journal of Experimental Pathology 411
Int. J. Exp. Path. (2014), 95, 411–417
tion, blood glucose level is an accurate predictor of outcome
in gallstone pancreatitis and an important criterion for the
Ranson score, which is used to assess the prognosis of AP
(Ranson et al. 1974; Rajaratnam & Martin 2006).
We have previously demonstrated in experimental settings
that diabetes indeed aggravates the local pathophysiological
process during acute as well as chronic pancreatitis (Zechner
et al. 2012, 2013, 2014). The purpose of this study was to
explore if the aggravation of AP by diabetes leads to
increased systemic inflammation, and if adequate alterations
in the lung can be observed.
Methods
Animals
Eight to 12-week-old C57BL/6J mice were allowed access
to water and standard laboratory chow ad libitum. The
mice were treated as published previously (Zechner et al.
2012). Diabetes was caused by i.p. injection of 50 mg/kg
streptozotocin (STZ; Sigma-Aldrich, Steinheim, Germany)
on 5 consecutive days (day 1-5), whereas AP was induced
on day 22 and day 23 by administration of eight i.p. injec-
tions per day of 50 lg/kg cerulein (Sigma-Aldrich) at a
rate of one every hour. All control mice were Sham-treated
appropriately (0.9% wt/vol. NaCl solution instead of ceru-
lein, 50 mmol/l sodium citrate pH 4.5 instead of STZ). At
2 h before induction of pancreatitis, and up to the time
point of tissue preservation, all mice received drinking
water containing 800 mg/l metamizol (Ratiopharm, Ulm,
Germany) and 1 g/l BrdU (Sigma-Aldrich Chemie GmbH).
For sampling blood and tissue the animals were anaesthe-
tized with 75 mg/kg ketamine (Bela-Pharm, Vechta,
Germany) and 5 mg/kg xylazine (Bayer Health Care,
Leverkusen, Germany). All experiments were executed in
accordance with German legislation, the local animal
wellfare committee and the EU-directive 2010/63/EU.
Analysis of plasma and tissue
Blood samples were taken 2 hours after the last cerulein
injection on day 23. A differential blood cell count was
performed with an automated hematology analyzer Sysmex
KX 21 (Sysmex Cooperation, Kobe, Japan) as previously
published (Bobrowski et al. 2013). Concentrations of inter-
leukin (IL)-6 were measured in blood plasma with com-
mercially available enzyme-linked immunosorbent assay
(ELISA) kits from Thermo Fisher Scientific (Rockford, IL,
USA) following the manufacturer’s instructions, and data
were plotted as fold induction compared to the average of
IL-6 in Sham-treated mice. Tissue samples were taken on
day 23 (2 hours after the last cerulein injection) or on
day 30 (7 days after the last cerulein injection). Naphthol
AS-D chloroacetate esterase (CAE) staining, primarily
staining neutrophil granulocytes, or hematoxylin/eosin
staining was performed on paraffin-embedded tissue to
evaluate lung inflammation and histology. To evaluate the
alveolar cellularity index (nuclei/septum), the number of
nuclei crossing three gridlines of the integrating eyepiece
(using a 1009 objective) was divided by the number of
septa crossing these gridlines (Tascilar et al. 2007; ). We
analysed 10 randomly chosen microscopic fields from each
lung. Cell death was analysed by immunohistochemistry
using a rabbit-anti-mouse cleaved caspase-3 (Asp175) anti-
body (Cell Signaling Technology Inc., Denver, USA, code
9661, dilution 1:500) and a HRP-conjugated goat-anti-rab-
bit secondary antibody (code P0448; Dako Deutschland
GmbH, Hamburg, Germany). Cell proliferation was evalu-
ated by immunohistochemistry using mouse anti-BrdU
(clone: Bu20a, dilution: 1:50) and the Universal LSABTM+
Kit/HRP kit (Dako Deutschland GmbH). Quantification of
inflammation, BrdU incorporation and cell death was per-
formed on 10 random fields per mouse using a 409
objective.
Statistics
Data are given as means and standard deviation respectively.
The significance of data was assessed by SigmaStat 3.5 soft-
ware (SigmaStat; Jandel Corporation, San Rafael, CA,
USA). In all cases where the assumption of normality or the
homogeneity of variance across groups failed, the Mann–
Whitney rank sum test was performed, including correction
of the a-error according to the Bonferroni probabilities for
repeated analysis. In other cases, the unpaired Student’s t
test including the correction of the a-error according to the
Bonferroni was performed. The criterion for significance
was P < 0.05 divided by the number of meaningful compari-
sons.
Results
Diabetes aggravates systemic inflammation during
pancreatitis
To evaluate if STZ-induced diabetes has an influence on
parameters of systemic inflammation during cerulein-
induced AP, the IL-6 concentration in plasma was
determined in cerulein-treated diabetic mice (STZ + Cer)
and compared to healthy normoglycaemic mice (Sham),
cerulein-treated normoglycaemic mice (Cer) and diabetic
mice without pancreatitis (STZ). Administration of cerulein
in normoglycaemic mice during the acute phase of pancrea-
titis (on day 23, 2 hours after the last cerulein administra-
tion) increased the IL-6 plasma concentrations when
compared to healthy mice (Figure 1a). STZ plus cerulein
treatment lead to an even more pronounced increase in IL-6
concentration when compared to Sham, cerulein or STZ-
treated mice (Figure 1a). Evaluation of the blood cell count
revealed that administration of cerulein only slightly reduced
the number of leucocytes in normoglycaemic animals (Fig-
ure 1b). However, STZ plus cerulein treatment lead to a sig-
nificant decrease in the number of leucocytes when
compared to cerulein-treated mice (Figure 1b). A decrease in
International Journal of Experimental Pathology, 2014, 95, 411–417
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the number of lymphocytes was observed after administra-
tion of cerulein in normoglycaemic mice compared to
healthy mice (Figure 1c). STZ plus cerulein treatment lead
to an even more pronounced decrease in the number of lym-
phocytes when compared to Sham, cerulein or STZ-treated
mice (Figure 1c). The number of monocytes plus granulo-
cytes was increased by cerulein administration, but was not
significantly influenced by STZ (Figure 1d).
Diabetes only marginally aggravates lung inflammation
during pancreatitis
To evaluate if the observed aggravation of systemic inflam-
mation by diabetes has an influence on lung inflammation,
infiltrating inflammatory cells were identified by CAE stain-
ing on lung sections on day 23 (Figure 2a–d). Administration
of cerulein in normoglycaemic or diabetic mice significantly
increased the number of CAE+ cells in the lung tissue when
compared to Sham or STZ-treated mice (Figure 2e). STZ
plus cerulein treatment lead to a slight increase (P = 0.023)
in the number of CAE+ cells when compared to cerulein-
treated mice (Figure 2e). The alveolar cellularity index was
marginally increased by cerulein treatment (P = 0.143), but
barely influenced by STZ treatment (Figure 2f).
Diabetes does not induce cell death in the lung
epithelium
To evaluate if STZ-induced diabetes has an influence on cell
death in the lung during the acute phase of pancreatitis (on
day 23, 2 hours after the last cerulein administration),
cleaved caspase-3+ cells were identified by immunohisto-
chemistry (Figure 3a). However, the administration of
cerulein, STZ or STZ plus cerulein did not result in an
increased number of cleaved caspase-3+ cells in the lung
when compared to Sham-treated animals (Figure 3b). To
evaluate if this lack of cell death in the lung epithelium might
be caused by inadequate severity of pancreatitis we evaluated
the histology of the pancreas on day 23 and on day 30. Nor-
mal histology of the pancreas was observed in Sham and
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Figure 1 Diabetes aggravates
pancreatitis induced systemic
inflammation. The concentration of
IL-6 in blood plasma (a), and the
concentration of leucocytes (b),
lymphocytes (c) or monocytes plus
granulocytes (d) in the blood was
determined on day 23 (2 hours after
the last cerulein administration) in
control mice (Sham), mice with AP
(Cer), diabetic mice (STZ) and diabetic
mice with AP (STZ + Cer). Bar charts
indicate the average and standard
deviation. The number of animals
evaluated for each cohort was n = 8
(Sham), n = 19 (Cer), n = 11 (STZ),
n = 21 (STZ + Cer) in panel a and
n = 6 (Sham), n = 20 (Cer), n = 7
(STZ), n = 19 (STZ + Cer) in panel b
to d. Significant differences between the
cohorts are indicated, Mann–Whitney
rank sum test: *P ≤ 0.001 (a, c, d),
*P = 0.008 (b), #P ≤ 0.001 compared
to Sham-treated mice (a, c, d).
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STZ-treated mice (data not shown). In cerulein-treated mice
features of AP such as oedema, and tissue-infiltrating inflam-
matory cells were observed on day 23, but pancreatitis was
reversible as judged by histology of the pancreas on day 30
Figure 2 Diabetes and pancreatitis influence lung inflammation
and alveolar cellularity on day 23. Representative images of
CAE+ inflammatory cells in the lung in control mice (a), mice
with AP (b), diabetic mice (c) and diabetic mice with AP (d).
The number of CAE+ inflammatory cells per field (e) and the
alveolar cellularity index (f) was quantified. Bar charts indicate
the average and standard deviation. The number of animals
evaluated for each cohort was n = 9 (Sham), n = 17 (Cer),
n = 12 (STZ), n = 17 (STZ + Cer) in panel e and n = 4 (Sham),
n = 5 (Cer), n = 4 (STZ), n = 6 (STZ + Cer) in panel f.
Significant differences between the cohorts are indicated,
Mann–Whitney rank sum test: *P < 0.001, #P < 0.001
compared to Sham-treated mice. Bar = 20 lm.
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Figure 3 Diabetes does not enhance cell death in the lung
epithelium on day 23. Representative image of cleaved caspase-
3+ cells in the lung of a cerulein-treated mouse (a). The number
of cleaved caspase-3+ cells in the lung epithelium per field (b)
was quantified. Bar charts indicate the average and standard
deviation. The number of animals evaluated for each cohort
was n = 4. No significance was observed by Mann–Whitney
rank sum test followed by Bonferroni correction for repeated
analysis. Bar = 50 lm.
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(Figure 4a,b). In STZ plus cerulein-treated mice an even
stronger induction of oedema and increased infiltration of
inflammatory cells was observed in the pancreas on day 23
when compared to cerulein-treated mice (Figure 4a,c). In
addition, AP continued until day 30 leading to a massive
reduction of acinar cells (Figure 4d). These data suggest that
cerulein induces a mild reversible form of pancreatitis,
whereas STZ plus cerulein treatment leads to a more severe
form of pancreatitis resulting in an impressive difference in
the histology of the pancreas on day 30.
Analysis of inflammation and cell death on day 30
On day 30, STZ plus cerulein-treated mice have a margin-
ally increased number of CAE+ cells (P = 0.114) in the lung
epithelium when compared to cerulein-treated mice (Fig-
ure 5a). In addition, the alveolar cellularity index was also
slightly increased (P = 0.114) by STZ plus cerulein treat-
ment when compared to cerulein-treated mice (Figure 5b).
However, we observed no increase in the number of cleaved
caspase-3+ cells in STZ plus cerulein-treated mice when
compared to cerulein-treated mice (Figure 5c). As lung
injury can cause proliferation of lung epithelial cells, we also
quantified BrdU incorporation into the nuclei of lung epithe-
lial cells during 8 days of AP (day 22–30). We observed no
increase in the number of BrdU+ cells in STZ plus cerulein-
treated mice when compared to cerulein-treated animals
(Figure 5d).
Discussion
The presented data demonstrate that diabetes during AP (i)
enhances IL-6 concentration in blood plasma while decreas-
ing the number of lymphocytes in the blood, (ii) only mar-
ginally increases pancreatitis induced lung inflammation, but
(iii) does not lead to major cell death or proliferation in the
lung epithelium. We conclude that diabetes has a fundamen-
tal influence on the progression of pancreatitis at a local
level as published previously (Zechner et al. 2012, 2013,
2014) and can also increase systemic inflammatory parame-
ters such as IL-6 concentration in blood plasma. However,
these data also suggest that the observed strong aggravation
of pancreatitis by diabetes leads neither to strong enhance-
ment of lung inflammation nor to induction of cell death in
the lung epithelium.
Redundant administration of cerulein causes an oedema-
tous form of AP, which is associated with lung inflamma-
tion and a very mild form of lung injury (Elder et al.
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Figure 4 Histology of the pancreas after induction of acute
pancreatitis. Representative images of hematoxylin/eosin-stained
pancreas sections of cerulein (a, b) or STZ plus cerulein (c, d)-
treated mice on day 23 (a, c) and day 30 (b, d). Bar = 50 lm.
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Figure 5 Evaluation of inflammation and cell death in the lung
on day 30. The number of CAE+ inflammatory cells per field
(a), the alveolar cellularity index (b), the number of cleaved
caspase-3+ cells in the lung epithelium per field (c) and the
number of BrdU+ cells per field (d) were quantified. Bar charts
indicate the average and standard deviation. The number of
animals evaluated for each cohort was n = 4. No significance
was observed by Mann–Whitney rank sum test followed by
Bonferroni correction for repeated analysis.
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2011). This animal model system should be ideal to test if
additional parameters such as diabetes aggravate lung
injury, but will not detect a possible inhibition of pancrea-
titis induced lung injury. The seemingly contradictory
result, that diabetes worsens AP leading to a severe form
of pancreatitis, but does not cause lung injury, could be
explained by the following assumption. Possibly diabetes
aggravates pancreatitis, but at the same time reduces the
risk for lung injury. This conclusion that lung injury is not
aggravated but rather reduced by diabetes is supported by
clinical as well as experimental studies. For example, dia-
betes predicts mortality in critically ill patients, but is not
associated with ALI (Koh et al. 2012). A meta-analysis also
suggests that pre-existing diabetes leads to reduced rather
than increased risk of lung injury in critically ill patients
(Gu et al. 2014). Diabetes also does not increase, but
reduces the risk for lung dysfunction in patients with sepsis
(Esper et al. 2009; Yang et al. 2011). Experiments in rats
demonstrate that sepsis-induced ALI is milder in diabetic
rats than in normoglycaemic controls (Filgueiras et al.
2012). Although a few studies suggest that in specific
model systems, pre-existing diabetes can also increase the
risk of lung injury (Hagiwara et al. 2011; Xiong et al.
2013) a consensus seems to develop that diabetes is protec-
tive against lung injury (Honiden & Gong 2009). Our pre-
sented data and the above cited literature, therefore,
suggest that it might be especially valuable to carefully
adjust glucose concentration to avoid local complications
during AP, but that hyperglycaemia might not increase the
risk of lung injury during AP.
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Abstract
Diabetes and fibrosis can be concurrent processes in several diseases such as cystic fibrosis or chronic pancreatitis. To evaluate
whether diabetes can influence fibrosis and thus aggravate the pathological process, the progression of chronic pancreatitis was
assessed in diabetic and non diabetic mice. For this purpose, insulin producing beta-cells in C57Bl/6 J mice were selectively
impaired by administration of streptozotocin. Chronic pancreatitis was then induced by repetitive administration of cerulein in
normoglycaemic and hyperglycaemic mice. Diabetes caused enhanced collagen I deposition within three weeks of the onset of
chronic pancreatitis and increased the proliferation of interstitial cells. This was accompanied by an increased number of inter-
lobular fibroblasts, which expressed S100A4 (fibroblast-specific protein-1) and stimulation of a-smoothmuscle actin expression of
pancreatic stellate cells. In addition, the observed aggravation of chronic pancreatitis by diabetes also led to a significantly
enhanced atrophy of the pancreas, increased infiltration of inflammatory chloracetate esterase positive cells and enhanced
acinar cell death. We conclude that diabetes has a detrimental influence on the progression of chronic pancreatitis by aggravating
fibrosis, inflammation and pancreatic atrophy.
Keywords: Diabetes, chronic inflammation, fibrosis, pancreatic stellate cells, S100A4, proliferation in islets of Langerhans
Experimental Biology and Medicine 2014; 239: 670–676. DOI: 10.1177/1535370214527890
Introduction
Fibrosis occurs in many tissues as a result of inflammation
or damage and can have a devastating effect on the function
of organs, as observed, for example in liver cirrhosis, pul-
monary fibrosis or chronic pancreatitis.1–3 In chronic pan-
creatitis fibrosis is caused by stimulation of interstitial
cells called pancreatic stellate cells.4 Upon stimulation stel-
late cells start to express a-smooth muscle actin, which is fol-
lowed by deposition of extracellular matrix.4 These cells
can be found at the basolateral aspect of acinar cells
(periacinar cells) or in between lobuli (interlobular
fibroblasts).5–7
During some diseases, such as cystic fibrosis or chronic
pancreatitis, fibrosis is often accompanied by diabetes.1,3 In
particular, chronic pancreatitis is regularly associated with
diabetes.1 Some patients with beginning chronic pancrea-
titis may have either type 2 diabetes mellitus mostly due
to obesity or long-term type 1 diabetes, whereas patients
with longstanding chronic pancreatitis can develop type
3 c diabetes mellitus.8 The prevalence of diabetes in
chronic pancreatitis depends on aetiology, age, genetic
predisposition, degree of pancreatic damage, the presence
or absence of pancreatic calculi and the duration of the dis-
ease.1 For example, in one prospective cohort study with 500
patients the development of diabetes was observed in 83%
of patients with chronic pancreatitis.9 Chronic pancreatitis
causes type 3 c diabetes by reducing the beta-cell mass and
possibly by causing a reduced functionality of beta-
cells.10–12 Interestingly, it has also been documented that
diabetes is a mortality risk factor for chronic pancreatitis.13
This suggests that diabetes may also have an influence on
the progression of chronic pancreatitis. Surprisingly, no
experimental data exist to address the hypothesis if diabetes
influences fibrosis during chronic pancreatitis.
In this study, we explored whether diabetes influences
main features of chronic pancreatitis such as fibrosis,
inflammation and pancreatic atrophy. Our data demon-
strate that diabetes has a fundamental influence on the pro-
gression of chronic pancreatitis by enhancing collagen I
deposition and inducing the proliferation of interstitial
cells. In addition, diabetes enhances cell death of
acinar cells, increases the number of infiltrating inflamma-
tory cells and aggravates atrophy of the pancreas.
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Materials and methods
Animal husbandry and tissue collection
Eight- to twelve-week-old C57BL/6 J mice were either
sham- (Sham), cerulein- (Cer), streptozotocin- (STZ), or
streptozotocin plus cerulein- (STZ þ Cer) treated (Figure
1). Diabetes was induced in two cohorts (STZ, STZ þ Cer)
by intraperitoneal injection of 50 mg/kg streptozotocin
(Sigma-Aldrich, St Louis, MO, USA) daily on day 1–5 of
experimental design. Chronic pancreatitis was then
induced in two cohorts (Cer, STZ þ Cer) by administration
of three intraperitoneal injections of 50mg/kg cerulein
(Sigma-Aldrich) at a rate of one every hour three times a
week (thus Monday, Wednesday and Friday) over a period
of three weeks (Figure 1). All control mice were sham-
treated with appropriate vehicles (0.9% wt/vol. saline solu-
tion instead of cerulein; 50 mmol/L sodium citrate pH 4.5
instead of STZ). All four cohorts of mice received drinking
water containing 800 mg/L of metamizol to prevent poten-
tial pain caused by pancreatitis (Ratiopharm, Ulm,
Germany). In addition, all mice received 1 g/L 5-bromo-
2’-deoxyuridine (BrdU, Sigma-Aldrich) during the entire
period of chronic pancreatitis in the drinking water, in
order to evaluate cell proliferation. Blood samples for
assessing amylase and lipase activity were taken 2 h after
the third cerulein injection on day 22, or on day 47, one
week after the last cerulein injection. Pancreatic tissue was
sampled on day 26, 2 h after the last cerulein administration
or on day 47. Blood glucose was measured with the blood
glucose metre Contour (Bayer Vital, Leverkusen, Germany)
on day 1 before the first STZ injection and on day 22 before
the first cerulein injection. For retrobulbar blood sampling
and tissue collection, the animals were anaesthetised with
75 mg/kg ketamine (bela-pharm, Vechta, Germany) and
5 mg/kg xylacine (Bayer Health Care, Leverkusen,
Germany). After the start of laparotomy, the tissue was iso-
lated within a maximum of 5 min and fixed in 4% (wt/vol.)
phosphate-buffered formalin for 2–3 days. In addition,
squeezing of the pancreas with tweezers was avoided, in
order to minimise tissue damage. All experiments were per-
formed in accordance with German legislation and the prin-
ciples of laboratory animal care.
Analysis of plasma and tissue
To assess acinar cell damage, the activity of lipase and amyl-
ase in blood plasma was analysed using the Cobas c111
spectrophotometer (Roche Diagnostics, Mannheim,
Germany). Pancreatic atrophy was quantified as pancreas
to body weight ratio and the pancreas was processed as
described previously for histological staining.14 To evaluate
the cellular inflammatory response, which is characterised
by infiltration of granulocytes during cerulein-induced
pancreatitis,15 naphthol AS-D chloroacetate esterase (CAE)
staining was performed on paraffin embedded tissue. Cell
death was analysed using the ApopTag Plus Peroxidase in
situ detection kit (Millipore, Eschborn, Germany). Cell pro-
liferation or fibrosis was evaluated by immunohistochem-
istry using mouse anti-BrdU (clone Bu20a, dilution 1:50),
rabbit anti-collagen-I (Abcam, Cambridge, UK, code ab
34710, dilution 1:200), goat anti-S100A4 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, code sc-19949, dilution
1:50) or rabbit anti-a-smooth muscle actin (Abcam, ab5694,
dilution 1:800). All immunohistochemical procedures were
performed using the Universal LSABþ Kit/HRP as source
for appropriate secondary antibodies (Dako, Hamburg,
Germany). Planimetric analysis of collagen I positive
areas in the pancreas was performed on 10 randomly
chosen pictures (taken with a 40 x objective) of pancreatic
tissue per mouse by using Adobe Photoshop CS5 (Adobe,
San Jose, CA, USA).
Statistics
Data presentation and statistics were performed as
described previously.14 The significance of differences was
evaluated using a Mann–Whitney rank-sum test, followed
by the correction for the accumulation of the a error by
considering the number of meaningful comparisons.
Differences with P 0.05, divided by the number of mean-
ingful comparisons were considered to be significant.
Differences with P< 0.08, divided by the number of mean-
ingful comparisons, were considered to indicate a tendency.
Results
Quality control of induced diabetes and chronic
pancreatitis
At the beginning of the experiment, on day 1, all four
cohorts of mice had similar blood glucose concentrations
(Sham: 6.8/6.6–8.3, Cer: 7.7/7.0–8.8, STZ: 7.1/6.3–7.9, STZ
þCer: 7.0/6.0–8.2, median/interquartile range in mmol/L).
Injection of STZ caused a strong rise in blood glucose con-
centration in STZ- and STZ plus cerulein-treated cohorts by
day 22 when compared to control cohorts (Figure 2a). Thus,
the blood glucose concentrations of the STZ versus STZ
plus cerulein cohorts were comparable to each other, but
were significantly increased in comparison to sham- and
cerulein-treated mice. Two hours after the first three con-
secutive cerulein or sham injections on day 22, lipase and
day 1 2 3 4 5 38 43 4736333129262422 40
STZ+Cer
Sham
Cer
STZ
Sham
1x STZ
1x STZ
Sham Sham
3x Cer
Sham
3x Cer
BrdU
Figure 1 Experimental protocol. In two cohorts (STZ, STZþ Cer) diabetes was
induced by intraperitoneal injection of 50mg/kg streptozotocin on day 1–5 of the
experimental paradigm. Control cohorts (Sham, Cer) were sham-treated in the
same manner by injection of 50mmol/L sodium citrate pH 4.5. In two cohorts
(Cer, STZ þ Cer) chronic pancreatitis was then induced from day 22 to day 40 by
administration of three intraperitoneal injections of 50 mg/kg cerulein at a rate of
one every hour on Monday, Wednesday and Friday. Control cohorts (Sham, STZ)
were sham-treated in the same manner with 0.9% wt/vol. saline. In order to
evaluate cell proliferation, all mice received 1g/L BrdU during the entire period of
chronic pancreatitis in the drinking water. The tissue was either collected on day
26 or on day 47
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amylase activity in blood plasma was assessed. Lipase
activity increased significantly in cerulein as well as STZ
plus cerulein-treated mice when compared to control
cohorts (Figure 2b), verifying the onset of pancreatic
tissue injury. The analysis of amylase activity confirmed
the lipase activity data, since amylase activity increased sig-
nificantly in cerulein as well as STZ plus cerulein-treated
mice when compared to control cohorts (Figure 2c). On day
47, one week after the last episode of cerulein-induced
chronic pancreatitis, both lipase as well as amylase activity
returned to physiological levels (data not shown).
Diabetes enhances collagen I deposition and
proliferation of interstitial cells
Immunohistochemical analysis of the pancreas on day 47
revealed barely any collagen I deposition in sham-treated or
STZ-treated mice, whereas in cerulein and especially STZ
plus cerulein-treated mice prominent collagen I deposition
was observed (Figure 3a). Planimetric evaluation of the col-
lagen I positive tissue area affirmed a significant increase in
collagen I deposition in the pancreas of cerulein-treated
mice when compared to sham-treated animals (Figure 3b).
Collagen I deposition in STZ plus cerulein-treated mice was
increased, when compared to sham, STZ- or cerulein-trea-
ted animals (Figure 3b). In order to assess if this increase in
collagen deposition correlates with an expansion of inter-
stitial cell populations, the BrdU incorporation in interstitial
cells was evaluated on day 26. Proliferation of interstitial
cells was increased in the mouse cohort treated with ceru-
lein and a major increase in proliferation of interstitial cells
was observed in mice treated with STZ plus cerulein
(Figure 3c). Analysis of the percentage of BrdUþ cells in
the islets of Langerhans on day 26 revealed reduced prolif-
eration of islet cells during chronic pancreatitis, but
increased proliferation in diabetic mice (Sham: 1.45/0.65–
2.23, Cer: 0.71/0.00–0.95, STZ: 2.06/1.9–3.23, STZ þ Cer:
1.57/0.51–2.32, median/interquartile range in percentage
of BrdUþ cells, the differences were not significant).
Diabetes, therefore, significantly stimulates the expansion
of interstitial cells and enhances collagen I deposition
during chronic pancreatitis, but only moderately stimulates
the proliferation of islet cells.
Diabetes stimulates activation of pancreatic stellate
cells
Collagen can be produced by stimulated fibroblasts. In the
pancreas, especially stellate cells have been reported to pro-
duce collagen during pancreatitis.7 Thus, we evaluated the
expression of S100A4 (fibroblast-specific protein-1), as gen-
eral fibroblast marker and a-smooth muscle actin, which is
expressed by pancreatic stellate cells only after tissue injury.
Immunohistochemical analysis of the pancreas revealed
that interlobular fibroblasts express S100A4 (fibroblast-spe-
cific protein-1) independent of diabetes or pancreatitis
(Figure 4a). In cerulein and especially STZ plus cerulein-
treated mice, however, more S100A4 positive interlobular
cells could be observed on day 26 (Figure 4a). The expres-
sion of a-smooth muscle actin was observed in azinar as
well as interlobular stellate cells only after cerulein and
STZ plus cerulein treatment, whereas in all animals a-
smooth muscle actin positive blood vessels could be noticed
(Figure 4b). The intensity of a-smooth muscle actin staining
of periacinar cells as well as interlobular stellate cells was
increased in STZ plus cerulein-treated mice in comparison
to cerulein-treated mice. This suggests that diabetes
enhances the activation of stellate cells during chronic
pancreatitis.
Diabetes enhances pancreatic atrophy and alters pan-
creas histology
Analysis of the pancreas on day 47 revealed a distinct atro-
phy of the pancreas in cerulein-treated mice compared to
sham-treated animals (Figure 5a). This atrophy was even
more pronounced in STZ plus cerulein-treated mice,
when compared to sham-, STZ- or cerulein-treated animals
(Figure 5a). Haematoxylin/eosin staining of sections on day
47 revealed no pathological features in the exocrine tissue in
sham- and STZ-treated mice, whereas cerulein and espe-
cially STZ plus cerulein-treated animals had fields
of acinar cells interrupted by interstitial cells (Figure 5b).
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streptozotocin- (STZ) or streptozotocin plus cerulein (STZþCer)-treated mice. Box plots indicate the median, the 25th and 75th percentiles in the form of a box, and the
10th and 90th percentiles in the form of whiskers. Significant differences between the cohorts are indicated, *P0.001
672 Experimental Biology and Medicine Volume 239 June 2014
. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
 at Universitaetsbibliothek Rostock on January 6, 2015ebm.sagepub.comDownloaded from 
In addition, beginning acinar to ductal metaplasia was often
observed in STZ plus cerulein-treated mice (Figure 5b).
Diabetes enhances inflammation and cell death
On day 26, a significantly increased number of CAE posi-
tive infiltrating inflammatory cells were observed in the
pancreas of cerulein-treated mice when compared to
sham-treated animals (Figure 6a). STZ plus cerulein-treated
mice showed an even stronger increase in the number of
CAEþ inflammatory cells when compared to sham-, STZ- or
cerulein-treated animals (Figure 6a). Cell death of acinar
cells was modestly increased in the mouse cohort treated
with cerulein, whereas a major increase in dying acinar cells
was observed in mice treated with STZ plus cerulein
(Figure 6b).
Discussion
The presented data demonstrate that diabetes (i) enhances
collagen I deposition, (ii) increases proliferation of intersti-
tial cells, (iii) stimulates the expression of a-smooth muscle
actin in stellate cells, (iv) aggravates inflammation and (v)
induces cell death during chronic pancreatitis. Diabetes
leads, therefore, to a detrimental increase in fibrosis and
pancreatic atrophy within three weeks of chronic pancrea-
titis. Thus, diabetes fundamentally aggravates the progres-
sion of chronic pancreatitis.
The observations in this study correlate well with a clin-
ical study describing that diabetes is a mortality risk factor
for chronic pancreatitis.13 A detrimental influence of dia-
betes has also been discussed in the context of acute pan-
creatitis.15 For example, patients with diabetes have a
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higher risk of acute pancreatitis and hyperglycaemia may
predispose patients with acute pancreatitis to systemic
organ failure.16–19 In addition, blood glucose level is an
accurate predictor of outcome in gallstone pancreatitis
and an important criterion for assessing the prognosis of
acute pancreatitis by the Ranson score.20,21 However, a def-
inite cause and effect relationship between diabetes and
pancreatitis cannot be evaluated in these clinical studies,
but needs to be addressed in an experimental setting.
Only few experimental data are available that address
the question whether diabetes influences pancreatitis. For
example, hyperglycaemia correlates with increased inflam-
mation during chronic pancreatitis in CCR2 loss of function
mice.22 In addition, we demonstrated in a previous study
that diabetes increases tissue damage and reduces regener-
ation in the pancreas after acute pancreatitis.23 Both
publications are consistent with this study and support
the hypothesis that diabetes has a major influence on the
exocrine compartment during pancreatitis.
The observed aggravation of chronic pancreatitis by dia-
betes raises the question whether diabetes has a direct effect
on acinar cells and stellate cells. A direct effect of diabetes
on acinar cells has been described previously and has been
summarised as so called endocrine to exocrine axis hypoth-
esis.1,24 For example, numerous publications document that
diabetes reduces the secretion of digestive enzymes such as
amylase.25–27 These observations might partially explain
exocrine deficiency that can be observed in some diabetic
patients.28 However, it seems to be counterintuitive that the
aggravation of pancreatitis by diabetes could be explained
by exocrine insufficiency of acinar cells. It is more likely that
diabetes has a profound influence on pancreatitis through
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Figure 6 Diabetes activates inflammation and cell death. Indicated parameters were assessed in control mice (Sham) and cerulein- (Cer), streptozotocin- (STZ) or
streptozotocin plus cerulein- (STZþCer) treated cohorts on day 26. The number of CAEþ inflammatory cells per field was quantified (a) and cell death was evaluated by
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Figure 5 Diabetes aggravates pancreatic atrophy, and alters the histology. Pancreas to body weight ratio was determined in control (Sham) and cerulein- (Cer),
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other mechanisms such as modulation of the inflammatory
response or the aggravation of cell death.
A direct effect of diabetes on stellate cells is supported by
some in vitro experiments. For example, high glucose con-
centration has been reported to induce proliferation and
synthesis of extracellular matrix proteins in interstitial
cells which were isolated from the pancreas.29–31
However, since STZ-treated hyperglycaemic mice did not
have any obviously increased collagen I deposition or acti-
vation of stellate cells, higher glucose concentration alone
seems to be insufficient to induce fibrosis in vivo. Only in the
context of chronic pancreatitis we observed that diabetes
increased collagen deposition and activation of stellate
cells. This suggests that diabetes does not cause, but aggra-
vates inflammation-induced fibrosis. However, we cannot
determine if diabetes stimulates stellate cells directly or
indirectly, for example, via modulation of inflammation.
Nevertheless the characterised aggravation of fibrosis by
diabetes might be of clinical relevance, since some clinical
studies support this conclusion. For example, enhanced
fibrosis was observed post mortem in the pancreas of
patients with type 2 diabetes.32 In addition, enhanced fibro-
sis was also observed in other organs, in diabetic patients
with hepatitis C virus-infected liver and in patients suffer-
ing from idiopathic pulmonary fibrosis.33,34
As a secondary finding, we observed that diabetes mod-
erately increased proliferation of islet cells. This is consist-
ent with previously published data, describing increased
proliferation of b-cells as well as a- and d-cells in islets
after application of STZ.35–37 To our surprise application
of supraphysiological levels of cerulein, an analogue of
cholecystokinin, did not increase, but rather reduced the
proliferation of islet cells. This is not consistent with previ-
ous publications, which describe increased proliferation of
islet cells after application of moderate levels of cholecysto-
kinin.38,39 We assume that the inflammatory micromilieu
caused by supraphysiological levels of cerulein has the
opposite effect than administration of moderate concentra-
tions of cholecystokinin.
Recently, an intensified insulin therapy for patients with
pancreatitis as well as for critically ill patients in general has
been widely discussed.40–42 Since the danger of hypogly-
caemia in patients with pancreatitis is high, a conservative
insulin therapy is usually pursued.8,43,44 However, studies
also report that a more intensified careful insulin therapy
can be applied to patients with chronic pancreatitis without
increasing the incidence of hypoglycaemic events.42 Thus, if
diabetes had a similar strong negative effect on pancreatitis
in humans as observed in mice, a more intensified insulin
therapy could be beneficial to some patients.
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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.016Diabetes mellitus type 2 and chronic pancreatitis are regarded as risk factors for pancreatic cancer.
Pancreatic duct glands (PDGs) were recently described as a new compartment of the major duct in
humans and mice. To evaluate the influence of diabetes and chronic pancreatitis on PDGs, cerulein was
injected i.p., repetitively over 10 weeks, in mice exhibiting obesity and a type 2 diabeteselike
syndrome (B6.V-Lepob/ob) and in lean littermates. By using 5-bromo-20-deoxyuridine (BrdU), a label-
retaining cell population was characterized in PDGs. Cerulein administration led to more BrdUþ cells
in PDGs of obese mice compared with lean mice. The observed increase was specific to PDGs, because
BrdU incorporation in cells of the pancreatic duct was not increased. In addition, the expression of
distinct tumor markers in PDGs was characterized by Muc5ac, S100P, regenerating isletederived 3b,
14-3-3 s, and prostate stem cell antigen immunochemistry. Type 2 diabeteselike syndrome, accom-
panied by chronic pancreatitis, enhanced nuclear localization of S100P. Both risk factors for pancreatic
cancer also induced the production of Muc5ac and the nuclear localization of S100P. These results
demonstrate that diabetes and chronic pancreatitis jointly enhance BrdU incorporation and production
of pancreatic cancerespecific proteins in PDGs. The observed alterations suggest that pancreatic tumors
might originate from the newly discovered histomorphological structures, called PDGs, which could
represent a target for future anticancer therapies. (Am J Pathol 2013, 182: 965e974; http://
dx.doi.org/10.1016/j.ajpath.2012.11.016)Supported by the Forschungsförderung der Medizinischen Fakultät der
Rostocker Universität (FORUN) (project 889017) and a Studienstiftung des
deutschen Volkes e.V. stipend (A.B. and M.S.).The survival of patients with pancreatic cancer could only
be improved modestly during the past 30 years, resulting in
a 5-year survival rate of approximately 6% in the United
States.1 Basic knowledge about precancerous lesions might
improve our understanding about tumor progression; as
a long-term goal, this may allow the detection of pancreatic
cancer at a stage at which intervention could substantially
improve the survival rate (eg, in breast cancer).
Diabetes, obesity, and chronic pancreatitis are well-
characterized risk factors for this malignant disease. Dia-
betes mellitus type 2 increases the risk for pancreatic cancer
by 80%, and patients with pancreatic cancer who have
diabetes have a worse prognosis and a shorter survival time
than those without diabetes.2,3 Hyperinsulinemia itself also
increases the cancer risk up to 100%.4,5 Obesity is also
associated with a slightly increased risk of pancreatic
cancer, 19% in obese people, per a meta-analysis of 14
studies.6 Chronic pancreatitis is a major risk factor for the
development of pancreatic cancer. The lifetime cumulativestigative Pathology.
.probability of developing pancreatic cancer in the overall
population is up to 1%.7 Ten years after the diagnosis of
pancreatitis, the cumulative risk of pancreatic cancer is up to
1.8%;8 in hereditary pancreatitis, the cumulative risk of
developing pancreatic cancer is up to 44%.9
Concerning the histopathological characteristics, >80% of
the pancreatic tumors are classified as pancreatic ductal
adenocarcinoma (PDA). Another tumor entity in the pancreas
with increasing importance during the past few years is the
intraductal papillary mucinous neoplasm (IPMN). IPMNs
account for 3% to5%ofpancreatic tumors.10 IPMNsarise from
the pancreatic main duct or its major branches and display
different degrees of mucin secretion, cystic dilatation, and
invasiveness. They are classified into benign, borderline, and
malignant noninvasive and invasive lesions. Approximately
Bobrowski et al40% of all resected IPMNs are invasive carcinoma.11,12 The
advanced-stage invasive IPMN has a similar poor prognosis,
such as PDA.13 However, IPMNs themselves are also dis-
cussed as precursors of PDAs.10,14,15
There are many sites in the pancreas considered as the
origin for pancreatic cancer. The best-characterized precursor
lesion for PDAs is pancreatic intraepithelial neoplasia
(PanIN). PanINs are histologically characterized by a papil-
lary or flat (<5-mm) epithelial, noninvasive lesion, contain-
ing mucins. They usually arise in small ducts (<5 mm).15
PanINs might originate from the pancreatic duct epithelium
or acinar cells by acinar-to-ductal metaplasia (ADM).16e18
Recently, new compartments of the pancreatic duct, the
pancreatic duct glands (PDGs), were described in humans
and mice.19 PDGs are blind-ending, mucin-producing out
pouches, which are primarily located in the proximal ductal
system near the ampullary region. PDGs might be a distinct
compartment with possibly stem cellelike properties,
because they express developmental markers, such as Shh,
Pdx-1, and Hes-1.19 For this reason, PDGs are discussed as
the precursor lesion for PDA, PanINs, or IPMNs.19e21
The most established marker for pancreatic cancer is
carbohydrate antigen 19-9, which can predict resectability
and survival but fails in the screening of asymptomatic
subjects.22,23 Thus, for the characterization of precursor
lesions, other proteins, such as Muc5ac, S100P, regenerating
isletederived 3b (Reg3b), 14-3-3 s (stratifin), and prostate
stem cell antigen (PSCA), have been analyzed. The
production of Muc5ac characterizes gastrointestinal meta-
plasia and is typical for benign and malignant transformation
of pancreatic duct epithelium.24 Muc5ac production was
observed in PDA, PanINs, and IPMNs.25e27 S100P belongs
to the S100 family of calcium-binding proteins and is
produced in PDA, PanINs, and IPMNs.28,29 It can be detected
in the nucleus when interacting with S100PBPR.28 The
expression of Reg3b (or pancreatitis-associated protein) is
observed in PDA.30,31 Furthermore, proteins overexpressed
in PDA and PanINs are 14-3-3 s, which influence different
signal transduction pathways, and the cell surface glyco-
protein, PSCA.32e34
In this study, we demonstrate that risk factors for pan-
creatic cancer, such as diabetes, obesity, and pancreatitis,
specifically stimulate PDGs. These risk factors increase the
number of 5-bromo-20-deoxyuridine (BrdU) labeleretaining
cell population in PDGs and induce characteristic features
of pancreatic tumors, such as nuclear localization of S100P
or the production of Muc5ac.
Materials and Methods
Animals
Male B6.V-Lepob/ob mice were compared with male lean
B6.V-Lepþ/? littermates. The strain was originally pur-
chased from The Jackson Laboratory (Bar Harbor, ME).
The average  SD age of mice between the cohorts was966similar on day 71 of the experimental protocol (lean sham,
151  116 days; lean cerulein (Cer), 154  59 days; obese
sham, 194  84 days; obese Cer, 171  75 days), and no
correlation between age and the percentage of BrdUþ cells
or nuclear S100P staining in PDGs was observed. Animals
were kept on water and standard laboratory chow ad libi-
tum. All experiments were authorized by the local animal
welfare committee and were realized in accordance with the
German legislation and the principles of laboratory animal
care (NIH publication 85-23, revised 1985).
Induction of Chronic Pancreatitis and Analysis of
Blood Samples
Chronic pancreatitis was induced over 10 weeks by admi-
nistration of three i.p. injections of 50 mg/kg cerulein (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany), 3 days
a week, at a rate of one every hour per day. Control mice were
sham treated appropriately with 0.9% saline solution instead
of cerulein. For pain relief, 800 mg/Lmetamizol (Ratiopharm
GmbH, Ulm, Germany) was added to the drinking water
from day 1 to 71. The BrdU labeleretaining technique was
used to characterize cells that incorporate BrdU and retain
this analog of thymidine until day 71, by adding BrdU to the
drinking water from day 1 to 7 (1 g/L; Sigma-Aldrich Chemie
GmbH). For blood samples and organ extraction, animals
were anesthetized with 75 mg/kg ketamine (bela-pharm,
Vechta, Germany) and 5 mg/kg xylazine (Bayer Health Care,
Leverkusen, Germany).
Blood samples were taken on day 5, 2 hours after the last
cerulein injection, and on day 71. The concentration of
c-peptide in plasma was quantified on day 5 with the Bio-
Vendor Mouse C-Peptide ELISA Kit (BioVendor, Shibu-
kawa, Japan). The activity of amylase and lipase in plasma
was analyzed on days 5 and 71 using the cobas c111
spectrophotometer (Roche Diagnostics GmbH, Mannheim,
Germany). A differential blood cell count was performed on
day 71 with an automated hematology analyzer Sysmex
KX 21 (Sysmex Cooperation, Kobe, Japan). For the moni-
toring of diabetes, the blood glucose concentration was
measured weekly with the blood glucose meter Contour
(Bayer Vital GmbH, Leverkusen, Germany).
Histological and Immunofluorescent Staining
On day 71 (ie, 72 hours after the last cerulein injection), the
proximal half of the pancreas was placed lengthwise in
a biopsy cassette, fixed in 4% phosphate-buffered formalin,
and embedded in paraffin; sections (4 mm thick) of the pan-
creatic main duct were prepared. Serial sections in H&E stain
were obtained from one animal. To assess the mucin pro-
duction, PAS staining was performed. BrdU incorporation
was quantified with antibodies detecting mouse bromo-
deoxyuridine (clone, Bu20a; dilution, 1:50) with an Alcian
Blue counterstain for the detection of PDGs. Immunochem-
istry for Muc5ac was performed using the goat anti-mouseajp.amjpathol.org - The American Journal of Pathology
Stimulation of Pancreatic Duct GlandsMuc5ac antibody (sc-16903; dilution, 1:600; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). For 14-3-3 s immu-
nochemistry, a goat anti-mouse antibody (ab77187; dilution,
1:800; Abcamplc, Cambridge, UK), for PSCA immuno-
chemistry, a rabbit anti-mouse antibody (251249; dilution,
1:600; Abbiotec, LLC, San Diego, CA), for Reg3b immu-
nochemistry, a rat anti-mouse antibody (MAB5110; dilution,
1:800; R&D Systems Inc., Minneapolis, MN), and for S100P
immunochemistry, a rabbit anti-mouse antibody (ab86877;
prediluted; Abcamplc), were used. DNA damage was
assessed with the ApopTag Plus Peroxidase in situ detection
kit (Millipore, Eschborn, Germany). Immunofluorescence was
performed with a mouse anti-proliferating cell nuclear antigen
(PCNA)antibody (ab29; dilution, 1:1000;Abcamplc), amouse
anti-S100P antibody (ab86877; dilution, 1:5; Abcamplc), and
TOPRO-3 (Invitrogen, Carlsbad, CA).
The histological evaluation was performed using an
Olympus BX51 microscope (Olympus Corporation, Tokyo,
Japan), and the images were taken with cell^ D 2.5 (Olympus
Soft Imaging Solutions GmbH, Hamburg, Germany). All
immunohistochemical quantifications of nuclei, cytoplasm,
or cell number in PDGs were performed with a 100
objective. Immunofluorescence was evaluated on scanned
sections (2 mm thick) with a Zeiss LSM 780 confocal laserThe American Journal of Pathology - ajp.amjpathol.orgscanning microscope using a 63 objective (Carl Zeiss
Microscopy GmbH, Jena, Germany).Statistical Analysis
Data are presented as box plots indicating the median, the
25th and 75th percentiles in the form of a box, and the 10th
and 90th percentiles as whiskers. Significance tests and
evaluations of correlations were performed with SigmaStat
software version 3.5 (Jandel Corporation, San Rafael, CA).
Differences between groups were calculated using a Mann-
Whitney rank-sum test, followed by the correction for the
accumulation of the a error by considering the number of
meaningful comparisons. Differences with P < 0.05,
divided by the number of meaningful comparisons, were
considered to be significant. Differences with P < 0.08,
divided by the number of meaningful comparisons were
considered to indicate a tendency.Results
We compared obese mice (B6.V-Lepob/ob) with lean lit-
termates after the induction of chronic pancreatitis byFigure 1 Experimental protocol and charac-
terization of the diabetes type 2elike condition of
obese mice. A: Chronic pancreatitis was induced
by i.p. injection of cerulein in lean B6.V-Lepþ/?
(lean Cer) and B6.V-Lepob/ob (obese Cer) cohorts of
mice, three times a day, at a rate of one every
hour on the indicated days. Control lean (lean
Sham) and obese (obese Sham) mice received
0.9% saline solution each time instead of cerulein.
The blood glucose concentration was measured
once a week. Amylase and lipase activities were
analyzed on day 5 at 2 hours after last cerulein
injection and on day 71. Systemic leukocyte count
and tissue harvesting were performed on day 71.
B: The average blood glucose concentration of the
cohorts from day 2 to 71 is given. C: The
c-peptide concentrations in plasma on day 5 at 2
hours after the last cerulein injection are shown.
Box plots indicate the median, the 25th and 75th
percentiles in the form of a box, and the 10th and
90th percentiles as whiskers (lean Sham, n Z 10;
lean Cer, nZ 10; obese Sham, nZ 10; obese Cer,
n Z 10). Significant differences between the
cohorts are indicated, *P < 0.01 (B);
**P Z 0.002 (C).
967
Bobrowski et alcerulein or sham treatment (Figure 1A). The diabetes type
2elike condition of obese mice was characterized by
a higher blood glucose concentration compared with lean
littermates (Figure 1B) and increased insulin production
measured as c-peptide concentration in blood plasma
(Figure 1C).
As quality control for the induction of chronic pancreatitis,
we evaluated amylase activity, lipase activity, number of
leukocytes in the blood, and pancreas atrophy. Amylase
activity on day 5 was significantly higher in cerulein-treated
mice than in sham-treated animals, but normalized on day 71
(Figure 2A). We also noticed higher basal amylase activity in
obese mice on days 5 and 71 when compared with lean
littermates. Lipase activity was also significantly higher in200060000
e 
[U
/l]
1500
se
 
[U
/l] 40000
50000
se
[U
/L
]
e
[U
/L]
lip
as
e
500
1000
am
yla
s
10000
20000
30000
a
m
yla
s
lip
as
e
00
day 5 71 5 71 5 71 5 71
CerShamSham Cer
obeselean
day 5 71 5 71
SSham Cer
lean
600
700
8
10
9 /L
]
re
at
ic 
m
as
s 
[m
g]
300
400
500
4
6
e
u
ko
cy
te
co
u
n
t[x
10
re
a
tic
m
a
ss
[m
g]
pa
n
cr
100
200
2sy
st
em
ic
l
pa
nc
r
00
obese
CerShamSham Cer
lean
SSham Cer
lean
968cerulein-treated mice than in sham-treated animals on day 5
(Figure 2B). The number of leukocytes in blood decreased in
cerulein-treated mice compared with sham-treated animals,
possibly because of enhanced migration of leukocytes into
the inflamed pancreas (Figure 2C). The pancreatic mass was
also significantly reduced by cerulein treatment (Figure 2D).
Representative serial sections stained by H&E highlight
that PDGs are out pouches of the pancreatic duct and not
just branching ducts (Supplemental Figure S1). In addition,
mucin secretion as one of the characteristics of PDGs was
assessed by PAS staining. PASþ PDGs were observed close
to the pancreatic main duct in obese and lean mice.
However, the intensity of PASþ staining was increased in
cerulein-treated mice (Figure 3A). Interestingly, PASþ5 71 5 71
Cerham
obese
obese
Cerham
Figure 2 Repetitive cerulein administration
leads to chronic pancreatitis. A and B: Amylase
(A) and lipase (B) activities were determined on
days 5 and 71 (n Z 10 for each cohort). The
observed decrease in enzyme activities after 10
weeks of pancreatitis is typical for chronic
pancreatitis. C: On day 71, cerulein treatment
decreased the systemic leukocyte count (lean
Sham, n Z 9; lean Cer, n Z 10; obese Sham,
n Z 8; obese Cer, n Z 8). D: Cerulein treatment
decreased the pancreatic mass on day 71 (nZ 10
for each cohort). Box plots indicate the median,
the 25th and 75th percentiles in the form of a box,
and the 10th and 90th percentiles as whiskers.
Significant differences between the indicated
cohorts are noted *P  0.001 (A, B, and D);
**P  0.009 (C); yP  0.001 between days 5 and
71 of the same cohort; zPZ 0.002 between obese
mice and identically treated lean mice on the same
day.
ajp.amjpathol.org - The American Journal of Pathology
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duct. Cerulein-treated mice also had PASþ out pouches in
small peripheral ducts (Figure 3B). In addition, PASþ distal
structures, which look histologically different from PDGs,
were noticed (Figure 3C). These structures could be the
result of ADM. In cerulein-treated mice, we observed more
peripheral PASþ PDGs and ADMs when compared with
sham-treated mice (Figure 3, D and E).
Some cells, such as adult stem cells, often proliferate
slowly in vivo and, thus, retain certain incorporated labels
over a long period.35,36 To evaluate whether PDGs contain
a pool of label-retaining cells, BrdU incorporation during
the first week of chronic pancreatitis was quantified on day
71 (Figure 4, A and B). The percentage of BrdUþ cell nuclei
was significantly higher in cerulein-treated mice than in
sham-treated animals. Interestingly, BrdU incorporationThe American Journal of Pathology - ajp.amjpathol.orgafter cerulein treatment was significantly higher in obese
mice than in lean mice (Figure 4C). In contrast, the rate of
BrdU incorporation in epithelial cells of the main duct
was independent of genotype or treatment of the mice
(Figure 4D). BrdU incorporation might be caused by
proliferation or DNA damage, followed by DNA repair
during the first week of chronic pancreatitis. Evaluation of
DNA damage by an ApopTag kit, however, did not reveal
DNA damage in PDGs, although DNA damage was readily
detected in cells adjacent to PDGs (data not shown).
Some BrdUþ PDGs also produced Muc5ac, which char-
acterizes beginning metaplasia (Supplemental Figure S2).
The detection ofMuc5ac by immunochemistry revealed some
Muc5acþPDGs independent of genotype or treatment ofmice
(Figure 5A). However, an increased percentage of Muc5acþ
PDGs (P Z 0.015) was observed in cerulein-treated obeseFigure 3 PASþ structures demark higher mucin
production in cerulein-treated mice. A: PASþ PDGs
adjacent to the pancreatic main duct are shown.
The intensity increases with cerulein treatment. B:
PASþ PDGs in small peripheral ducts could be found
only in cerulein-treated mice. C: PASþ acinar
structures are mainly observed in cerulein-treated
mice. These structures do not resemble PDGs, but
have similar histological characteristics to ADM. D:
The number of PASþ PDGs located at small periph-
eral ducts is only detectable in cerulein-treated
mice. E: The number of PASþ ADMs is significantly
increased in cerulein-treated obese (ob) mice
compared with sham-treated obese mice. Box plots
indicate the median, the 25th and 75th percentiles
in the form of a box, and the 10th and 90th
percentiles as whiskers (n Z 6 for each cohort).
Significant differences between the indicated
cohorts are noted, *P  0.004. Tendentious
differences between the indicated cohorts are also
noted, yPZ 0.015. Scale barZ 20 mm.
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Figure 4 Diabetes and chronic pancreatitis
specifically induce BrdU incorporation in PDGs. BrdU
incorporation in nuclei was evaluated with anti-
bodies detecting BrdU. The PDGs were identified
with Alcian Blue counterstain. A: An overview over
the pancreatic main duct with PDGs displays modest
BrdU incorporation. Scale bar Z 100 mm. B: In
contrast to the duct, PDGs show an increased
incorporation of BrdU after cerulein treatment. Scale
barZ 20 mm. C: Quantification of the percentage of
BrdUþ cell nuclei in all PDGs adjacent to the main
duct. D: Quantification of the percentage of BrdUþ
cell nuclei in the epithelium of the main duct. Box
plots indicate the median, the 25th and 75th
percentiles in the form of a box, and the 10th and
90th percentiles as whiskers [lean Sham, nZ 9; lean
Cer, nZ 10; obese (ob) Sham, nZ 10; obese Cer,
n Z 10]. Significant differences between the indi-
cated cohorts are noted, *P  0.009.
Bobrowski et almice compared with cerulein-treated lean mice (Figure 5B).
Moreover, cerulein-treated obese mice have a significantly
higher percentage of Muc5acþ PDGs than sham-treated lean
or sham-treated obese mice (Figure 5B).
To evaluate the expression of pancreatic cancerespecific
genes in PDGs, we performed immunochemical analysis.
14-3-3 s localized at a similar intensity in the cytoplasm of
all cohorts (Figure 6A), and PSCA production also did not
differ between the cohorts (data not shown). Reg3b was
produced in the cytoplasm of PDGs, especially in cerulein-
treated mice (Figure 6B). A modest increase in the
percentage of Reg3b-producing cells in PDGs was observed
in cerulein-treated animals (Figure 6D). In addition,
cerulein-treated mice had more S100Pþ nuclei in PDGs
compared with sham-treated animals. Moreover, a higher
intensity of S100P staining was noticed in cerulein-treated
mice (Figure 6C). The percentage of S100Pþ nuclei in
PDGs of cerulein-treated obese mice was significantly higher
compared with sham-treated obese mice and with sham- or
cerulein-treated lean littermates (Figure 6E). To evaluate
whether nuclear localization of S100P and proliferation are
part of a coordinated response to risk factors for PDA, we
analyzed the colocalization of S100P with the PCNA in970PDGs. No significant difference in the percentage of PCNA-
positive cells was observed between distinct cohorts, possibly
because of the few PCNA-positive cells detected. Some, but
not all, of these PCNA-positive cells had S100P-positive
nuclei (Supplemental Figure S3, AeD). Consequently, no
correlation was observed between the expression of these
two proteins (Supplemental Figure S3E).Discussion
Understanding of pancreatic cancer precursor lesions is
important because early detection of such lesions could
provide new therapeutic options at a time point when this
disease is still curable.We observed that the newly discovered
PDGs are stimulated by several established risk factors for
pancreatic cancer. Chronic pancreatitis and type 2 dia-
beteselike syndrome in obese mice induced BrdU incorpo-
ration specifically in PDGs, but not in the epithelium of the
pancreatic main duct. Furthermore, both risk factors induced
characteristic features of pancreatic tumors, such as nuclear
localization of S100P and production of Muc5ac in PDGs.
However, we cannot differentiate if diabetes, obesity,ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Diabetes and pancreatitis induce
metaplasia of PDGs. A: Examples of Muc5ac
production in PDGs adjacent to the main duct. B:
Quantification of the percentage of Muc5acþ PDGs
adjacent to the main duct demonstrates a signifi-
cant increase of metaplasia dependent on diabetes
and pancreatitis. A PDG is declared as Muc5acþ if at
least one of the cells in a PDG exhibits Muc5acþ
cytoplasm. Box plots indicate the median, the 25th
and 75th percentiles in the form of a box, and the
10th and 90th percentiles as whiskers [lean Sham,
n Z 5; lean Cer, n Z 6; obese (ob) Sham, n Z 6;
obese Cer, n Z 6]. Significant differences between
the indicated cohorts are noted, *P  0.004.
Tendentious difference between the indicated
cohorts are noted yP Z 0.015. Scale bar Z 20 mm.
Stimulation of Pancreatic Duct Glandslipotoxicity, or a combination of these conditions alters the
physiological characteristics of PDGs in obese mice. In
addition, the Lepob/ob genotype alone had no major influence
on the physiological characteristics of PDGs. Compared with
lean littermates,Muc5ac expression, BrdU incorporation, and
nuclear localization of S100P were observed in PDGs of
obese mice primarily after stimulation with cerulein. More-
over, we observed increased BrdU incorporation, when
applying BrdU during the first week of chronic pancreatitis,
but no increased number of PCNAþ cells on day 71 of chronic
pancreatitis. This result might be explained by modest
proliferation of epithelial cells, which requires several days of
BrdU labeling to detect differences in the proliferation
capacity, or proliferation not stimulated by inflammatory
stimuli any more on day 71. Such a burnout phenomenon of
the pancreas is also supported by the analysis of lipase and
amylase activity, as presented in Figure 2, A and B. Thus, we
identified a BrdU labeleretaining cell population in PDGs
that either proliferates slowly, similar to adult stem cells in
other tissues, or even becomes postmitotic after the first week
of cerulein treatment.35,36 Alternatively, it might also be
feasible that BrdU might be incorporated in these cells by
DNA repair during the first week of pancreatitis. In summary,
these data suggest that a population of BrdU labeleretaining
cells within PDGs is influenced by risk factors for pancreatic
adenocarcinoma. Pancreatic tumors might, therefore, derive
from these histomorphological structures, called PDGs.The American Journal of Pathology - ajp.amjpathol.orgHowever, it is not known if PDGs are the origin for PDA
or IPMNs.19e21 The following reasons underline that PDGs
could produce IPMNs. IPMNs are similar to PDGs pre-
dominantly associated with the pancreatic main duct or its
branches.15 The expression of sonic hedgehog seems to be
an important step in the development of IPMNs37,38 and can
also be induced in PDGs.19 Thus, PDGs might be precursor
lesions for IPMNs. However, we interpret our data that
PDGs are more likely the origin for PDA rather than IPMNs
for the following reasons: i) our study demonstrates the
expression of 14-3-3 s, a protein typically expressed in
PDA, in PDGs, ii) Reg3b, another protein typically
produced in PDA, is induced in PDGs, and iii) diabetes is
a risk factor mainly for PDA.2 Because Muc5ac and S100P
are detected in IPMNs and PDA, both proteins indicate first
progression toward neoplasia, but cannot be used to dis-
tinguish between these two tumor entities. However, only
specific lineage-tracing studies in mice could finally reveal
if PDGs develop toward PDA or IPMNs.
It is widely accepted that PanINs are precursor lesions for
PDA. Several facts support this hypothesis. For example,
PanINs display metaplastic, hyperplastic, or dysplastic
alterations similar to histological alterations in PDAs.39 In
addition, genetically engineered mouse models (eg, using
Pdx1-Cre;LSL-KrasG12D mice) develop first PanINs and, at
a later time point, PDA, suggesting a PanIN to PDA model
of pancreatic cancer progression.16 Moreover, patients with971
Figure 6 Production of tumor-specific proteins
in PDGs. A: The PDGs of all cohorts produce 14-3-3
s mainly in the cytoplasm and rarely in the nuclei.
B: Reg3b localization in the cytoplasm was
increased in cerulein-treated lean or obese (ob)
mice. C: Diabetes and chronic pancreatitis increase
S100P localized in the nuclei of PDGs. D: Quanti-
fication of the percentage of Reg3bþ cytoplasm in
PDGs adjacent to the main duct. E: Quantification
of the percentage of S100Pþ cells in PDGs adjacent
to the main duct. A cell was declared S100Pþ if the
nucleus was S100Pþ. Box plots indicate the
median, the 25th and 75th percentiles in the form
of a box, and the 10th and 90th percentiles as
whiskers (lean Sham, n Z 9; lean Cer, n Z 10;
obese Sham, n Z 9 to 10; obese Cer, n Z 10).
Significant differences between the indicated
cohorts are noted, *P 0.006. Scale barZ 20 mm.
Bobrowski et ala strong family history for pancreatic cancer show PanIN
lesions before some of them develop cancer.40
In contrast, several studies cast doubt on the hypothesis that
pancreatic tumors originate from PanINs. The pure histo-
morphological ductal phenotype of the PDA and the expres-
sion of ductal markers do not allow a conclusion to a ductal
origin. In approximately 80% of patients with small inva-
sive carcinoma, high-grade PanINs are only observed within
10 mm from the infiltrating carcinoma. This suggests that
high-grade PanINs might be just intraductal extensions of the
tumor, rather than a residual precursor lesion.41 The inter-
pretation that PanINs could be the response of the duct
epithelium to a process of neoplasia in the pancreas, rather
than a precursor lesion, is also supported by the circumstance
that PanINs are observed in patients with pancreatic endo-
crine tumors or acinar cell carcinomas.42 Moreover, because
PanIN-1 is regularly detected in young individuals, it might972not be associated with an increased risk of developing pan-
creatic cancer.43 A correlation between the PDA risk factor,
pancreatitis, and the development of high-grade PanINs was
only observed in two studies, whereas most studies could not
confirm this observation.39 Furthermore, there is also no
correlation between the PDA risk factors, smoking, coffee
consumption, and diabetes, and the incidence of PanINs.43
These arguments raise doubt if PDA originates exclusively
from PanINs. In contrast to PanINs, we could demonstrate
that PDGs are susceptible to diabetes and pancreatitis. In
addition, PDGs are predominantly localized in the head or
neck of the pancreas, where 80% of PDA is localized.19,44
Thus, these circumstances suggest that PDA might be
derived from the ductal compartment called PDGs. This
hypothesis is also supported by the observation that cells with
stem cell character may reside within the duct epithelium.45
PDGs seem to have features of stem cell niches, such asajp.amjpathol.org - The American Journal of Pathology
Stimulation of Pancreatic Duct Glandsexpression of Shh, Pdx-1, and Hes-1,19e21 which are charac-
teristic during embryonic development of the pancreas.
Because the epitheliumof PDGs can showPanIN-like features,
such as pseudostratification, loss of polarity, and micro-
papillary architecture,20 we cannot exclude that PanINs or
PDGs might not represent mutual exclusive origins of PDA.
Thus, a progression from PDG to PanIN-like structures to
PDA might also be feasible.
Lately, multiple studies have focused on the question if
treatmentwith distinct antidiabeticmedication correlates with
increased risk for pancreatic cancer. The administration of
insulin or other oral antidiabetic drugs has increased cancer
risk.46 Interestingly, our study demonstrates increased BrdU
incorporation and metaplasia of PDGs in hyperinsulinemic
obese mice. This is consistent with the hypothesis that insulin
might increase cancer risk by stimulating PDGs. This
conclusion is also supported by another recently published
study demonstrating that exendin-4, a glucagon-like peptide-
1 analog, stimulates PDGs toward dysplasia.20 Thus, it is
crucial to pay attention on focal alterations in PDGs to eval-
uate adverse drug effects, such as increased cancer risk.
Early diagnosis and timely treatment of precursor lesions
before their progression to invasive cancer seems feasible,
because 5 years pass from the start of the parental, non-
metastatic founder cell, until the acquisition of metastatic
ability.47 For example, the observed pathological changes in
PDGs, such as Reg3b production, might provide the option to
diagnose pancreatic cancer at an early stage. In this context,
a novel positron emission tomographic/computed tomo-
graphic diagnostic option with Et-[18F]FDL was developed
for the detection of Reg3b overexpression in early pancreatic
carcinomas.48 Such screening methods could be rationally
applied in older individuals with new-onset diabetes, because
up to 80% of patients with a pancreatic cancer diagnosis
experience diabetes or impaired glucose tolerance, and most
of these patients have just recently developed diabetes.14,49
In summary, PDGs represent a promising histomorpho-
logical structure thatmight be the origin for pancreatic tumors.
The characterization of PDGs and the evaluation of pro-
gression toward malignancy might lead to a better under-
standing and, in the long run, to timely diagnostic options for
pancreatic cancer.
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Dietmar Zechner1*†, Tobias Radecke1†, Jonas Amme1, Florian Bürtin1, Ann-Christin Albert1, Lars Ivo Partecke2
and Brigitte Vollmar1Abstract
Background: We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation,
influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has
an impact on tumor growth.
Methods: Pancreatic carcinomas were assessed in a syngeneic orthotopic pancreas adenocarcinoma model after
injection of 6606PDA cells in the pancreas head of either B6.V-Lepob/ob mice exhibiting a type II diabetes-like
syndrome or normoglycemic mice. Chronic pancreatitis was then induced by repetitive administration of cerulein.
Cell proliferation, cell death, inflammation and the expression of cancer stem cell markers within the carcinomas
was evaluated by immunohistochemistry. In addition, the impact of the antidiabetic drug, metformin, on the
pathophysiology of the tumor was assessed.
Results: Diabetic mice developed pancreatic ductal adenocarcinomas with significantly increased tumor weight
when compared to normoglycemic littermates. Diabetes caused increased proliferation of cancer cells, but did
not inhibit cancer cell necrosis or apoptosis. Diabetes also reduced the number of Aldh1 expressing cancer cells
and moderately decreased the number of tumor infiltrating chloracetate esterase positive granulocytes. The
administration of metformin reduced tumor weight as well as cancer cell proliferation. Chronic pancreatitis
significantly diminished the pancreas weight and increased lipase activity in the blood, but only moderately
increased tumor weight.
Conclusion: We conclude that diabetes type II has a fundamental influence on pancreatic ductal adenocarcinoma by
stimulating cancer cell proliferation, while metformin inhibits cancer cell proliferation. Chronic inflammation had only a
minor effect on the pathophysiology of an established adenocarcinoma.
Keywords: Cancer stem cells, Cancer heterogeneity, Cancer cell plasticity, Aldh1, CD133Background
Pancreatic cancer is one of the most lethal malignancies.
The 5-year survival rate is despite therapeutic improve-
ments still only 6% [1]. More than 80% of the pancreatic
tumors are classified as pancreatic ductal adenocarcin-
oma (PDA). Novel therapies, but also the knowledge
about pathophysiological factors influencing the progres-
sion of this malignant disease might help to find combi-
nations of treatments to improve the survival rate. Key
pathophysiological processes of cancer such as recurrence* Correspondence: dietmar.zechner@uni-rostock.de
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1Institute for Experimental Surgery, Rostock University Medical Center,
Schillingallee 69a, 18057 Rostock, Germany
Full list of author information is available at the end of the article
© 2015 Zechner et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.after chemotherapy and metastasis have been suggested to
depend on cancer cell plasticity [2]. A prominent albeit
controversial hypothesis, describing one form of cancer
cell plasticity, is the concept of the existence of cancer
stem cells (CSC) [2]. Cancer stem cells (CSC) are assumed
to proliferate slowly, to have the capacity to renew them-
selves but also to give rise to distinct cell populations [3,4].
In PDA these cells have been reported to express specific
genes such as Aldh1 or CD133 [5-9].
Much is known about factors increasing the likelihood
to develop PDA. Identified risk factors include among
others chronic pancreatitis, long lasting diabetes, and obes-
ity [10]. Patients with chronic and especially hereditary
pancreatitis have a very high relative risk of developingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients with diabetes and obesity have a moderately in-
creased relative risk of 1.8 and 1.3 [12,13]. These studies
indicate that a substantial number of patients with PDA
also suffer from local inflammation or diabetes [10,14].
While some experimental studies exist that demonstrate
that pancreatitis and diabetes influence potential precursor
lesion of PDA such as PanINs or pancreatic duct glands
[15-18], it is not known, if these factors also influence the
pathophysiology of established carcinomas.
In order to evaluate if diabetes type II and inflammation
influence the pathophysiology of PDA, we established a
syngeneic orthotopic tumor model in mice and addressed
the questions, if pancreatitis or diabetes type II influence
cancer cell proliferation, cancer cell death, tumor-stroma
interaction or the cancer stem cell compartment in these
carcinomas.
Methods
Cell lines and cell culture
The cell lines, 6606PDA, 6606l and 7265PDA were a kind
gift from Prof. Tuveson, Cambridge, UK. The 6606PDA
and 6606l cell lines were originally isolated from a pancre-
atic adenocarcinoma or the respective liver metastasis of a
mouse with C57BL/6J background, which expressed the
KRASG12D oncogene in the pancreas (p48-cre induced ex-
pression of the oncogene) [19]. The 7265PDA cell line was
isolated from a pancreatic adenocarcinoma of a mouse,
which expressed the KRASG12D oncogene and in addition
the p53R172H allele in the pancreas (Pdx1-creER induced
expression of the two alleles). All cell lines were main-
tained in DMEM high glucose medium with 10% fetal calf
serum. For the injection of 6606PDA cells, subconfluent
cultures of cells were trypsinized and the trypsinization
was stopped by medium. After centrifugation the cells
were resuspended in PBS, the suspension was mixed with
an equal volume of Matrigel (BD Bioscience, San José,
Calif., USA, Nr: 354248) and kept on ice (at a concentration
of 1.25x107 cells/ml) until injection [20]. For re-isolation of
cells from carcinomas, tumors were isolated and cut up
into small pieces. The pieces and outgrowing cells were cul-
tivated in DMEM high glucose medium with 10% fetal calf
serum.
Evaluation of cells
Western blots were performed by separating cell lysate
on SDS polyacryl gels and transferring the proteins to a
polyvinyldifluoride membrane (Immobilon-P; Millipore,
Eschborn, Germany). The membranes were blocked with
2.5% (wt/vol.) BSA or 5% (wt/vol.) milk powder (for the
analysis of CD133) and incubated overnight at 4°C with
a rabbit anti-ALDH1a1 (Cell Signaling, Boston, USA, code
12035, 1:1000), rat anti-CD133 (eBioscience Inc., San
Diego, USA, code 14-1331, 1:500) or goat anti-GFAP(Abcam, Cambridge, UK, code ab53554,1:2000) anti-
body followed by incubation with a secondary peroxidase-
linked anti-rabbit antibody (Cell Signaling, code 7074,
1:1000), anti-rat antibody (Santa Cruz Biotechnology,
Santa Cruz, USA, code sc3823, dilution 1:10,000), or anti-
goat (Santa Cruz Biotechnology, sc-2020, 1:20.000). For
analysis of β-actin production, membranes were stripped,
blocked by 2.5% (wt/vol.) BSA and incubated with mouse
anti-β-actin antibody (Sigma-Aldrich, St Louis, MO, code
A5441, dilution 1:20000) followed by peroxidase-linked
anti-mouse antibody (Sigma-Aldrich, USA; code A9044,
dilution 1:60,000). Protein production was visualized by
luminol-enhanced chemiluminescence (ECL plus; GE
Healthcare, Munich, Germany) and digitalised with Chemi-
Doc XRS System (Bio-Rad Laboratories, Munich, Germany).
Signals were densitometrically assessed and corrected with
the signal intensity of β-actin (Quantity One; Bio-Rad
Laboratories).
For the analysis of CD133 mRNA by PCR total RNA
from cells or kidney was isolated using a RNeasy Mini
Kit (Qiagen, Germany) according to the manufacturer‘s
instructions. After a quality control of the isolated RNA
by agarose gel electrophoresis first strand cDNA was syn-
thesized by reverse transcription of 2 μg of total RNA
using oligo(dT)18 primer (Biolabs, Frankfurt am Main,
Germany) and Superscript II RNaseH-Reverse Transcript-
ase (Invitrogen, Karlsruhe, Germany). After heat inacti-
vation of the reverse transcriptase 1/20 of the cDNA
was amplified (27 cycles: 94°C for 30, 68°C for 40, 72°C
for 60 seconds) using CD133 specific primers (forward
primer: CCCTCCAGCAAACAAGCAAC, reverse primer:
ACAGCCGGAAGTAAGAGCAC) and the PCR product
of 325 bp was visualized by agarose gel electrophoresis.
For the quantification of cell proliferation rates, cells
were plated on 96 well plates, so that the cells were 20%
confluent, when BrdU was added to the medium. The
BrdU incorporation was measured after 24 hours of in-
cubation by the colorimetric cell proliferation assay as
specified by the manufacturer (Roche Applied Science,
Penzberg, Germany).
Animals
For this study male B6.V-Lepob/ob mice (obese mice) were
compared with male B6.V-Lep+/? littermates (lean mice).
The therapy with metformin was performed on male
C57BL/6J mice. The mouse strains were originally pur-
chased from The Jackson Laboratory (Bar Harbor, ME)
and bred in our local animal facility. For defining the
border between carcinoma and the desmoplastic reac-
tion, carcinoma cells were injected in the pancreas of
C57BL6-TgACTB-eGFP1Osb/J mice (with a corresponding
phenotype to lean B6.V-Lep+/? mice) [21]. Animals were
kept on water and standard laboratory chow ad libitum.
All experiments were executed in accordance with the
Zechner et al. BMC Cancer  (2015) 15:51 Page 3 of 13EU-directive 2010/63/EU and approved by the Landesamt
für Landwirtschaft, Lebensmittelsicherheit und Fischerei
Mecklenburg-Vorpommern (7221.3-1.1-069/12).
Syngeneic orthotopic carcinoma model
For injection of carcinoma cells general anesthesia was
induced in 93 ± 32 day old mice (average ± standard de-
viation) by 1.2-2.5% isoflurane. Perioperative analgesia
was ensured by sc injection of 5mg/kg carprofen (Rimadyl,
Pfizer GmbH, Berlin, Germany) and eyes were protected
by eye ointment. After shaving and disinfection of the
skin, the abdominal cavity was opened by transverse lapar-
otomy and the head of the pancreas was identified. Duo-
denum and pancreas was gently lifted by tweezers and 20
μl cell suspension containing 2.5x105 carcinoma cells were
injected slowly into the head of the pancreas using a pre-
cooled ga22s 710 RN 100 ul syringe (Hamilton Syringe,
Reno, Nev., USA). The pancreas was placed back into the
abdominal cavity and the cavity was closed by a coated
5-0 vicryl suture (Johnson & Johnson MEDICAL GmbH,
Norderstedt, Germany). The skin was then closed by a 5-0
prolene suture (Johnson & Johnson MEDICAL GmbH).
On day 8 after the injection of carcinoma cells, chronic
pancreatitis was induced over 2 weeks by administration
of three ip injections of 50 μg/kg cerulein (Sigma-Aldrich
Chemie GmbH), 3 days a week, at a rate of one every hour
per day. Control mice were sham treated appropriately
with 0.9% saline solution instead of cerulein and tissues
were analyzed on day 20. For the evaluation of the impact
of metformin on cancer pathophysiology 250 mg/kg
1,1-dimethylbiguanide hydrochloride (Sigma-Aldrich,
code 150959) was ip injected daily from day 8 to day 15
followed by daily injection of half of this dose from day
16 to day 29 and analysis of the tumor on day 29 (3-6
hours after the last metformin administration). Control
mice were sham treated appropriately with PBS instead
of metformin and tumors were analyzed on day 29. For
pain relief, 800 mg/L metamizol (Ratiopharm GmbH,
Ulm, Germany) was added to the drinking water during
the entire timespan of all in vivo experiments. In order
to assess cell proliferation 50 mg/kg 5-bromo-2-deox-
yuridine (BrdU) was injected ip 2.5 hours before tissue
asservation. For blood samples and organ harvest, animals
were anesthetized with 90 mg/kg ketamine (bela-pharm,
Vechta, Germany) and 7 mg/kg xylazine (Bayer Health
Care, Leverkusen, Germany).
Analysis of the blood
Blood glucose concentrations were measured with the
blood glucose meter Contour (Bayer Vital, Leverkusen,
Germany) on day 0 before injection of carcinoma cells
and on day 20 before the first cerulein injection of this
day. Blood samples for assessing lipase activity were taken
two hours after the third cerulein injection on day 8. Theactivity of lipase in blood plasma was analysed using
the Cobas c111 spectrophotometer (Roche Diagnostics,
Mannheim, Germany).Evaluation of tissue
The pancreas and tumor weight was measured after
careful separation of the carcinoma from the pancreas.
Evaluation of CD133 expression was performed on 7 μm
cryo-sections. These sections were fixed with 4% para-
formaldehyde in PBS for 15 min, reactive groups were
then quenched in 50 mM NH4Cl for 10 min and the cell
membranes were permeabilised with 0.3% saponin in PBS
for 15 min, before CD133 immunohistochemistry was
performed. All other data were obtained on 4μm paraffin
sections after fixing the tissue in 4% (wt/vol.) phosphate-
buffered formalin for 2–3 days. Histology was evaluated
after staining paraffin sections with haematoxylin and
eosin (H/E). Planimetric analysis of necrotic areas was per-
formed on 10 randomly chosen pictures (taken with a 20x
objective) of each carcinoma by using Adobe Photoshop
CS5 (Adobe, San Jose, CA, USA). Apoptosis was analysed
using the ApopTag Plus Peroxidase in situ detection kit
(Millipore, Eschborn, Germany). To evaluate the cellular
inflammatory response to cerulein injection, naphthol
AS-D chloroacetate esterase (CAE) staining was performed
on sections. Cell proliferation, chronic pancreatitis, and
desmoplastic reaction were evaluated by immunohisto-
chemistry using mouse anti-BrdU (Dako, Hamburg,
Germany, clone Bu20a, dilution 1:50), rabbit anti-collagen-I
(Abcam, code ab 34710, dilution 1:200), or rabbit anti-α-
smooth muscle actin (Abcam, code ab5694, dilution 1:800)
antibody. To verify desmoplastic reaction by the host,
carcinoma cells were assessed in GFP expressing mice
with goat anti-GFP antibody (Gene Tex, San Antonio,
Texas, USA, GTX26673, 1:500). Cancer cells were fur-
ther characterized by immunohistochemistry using rabbit
anti-ALDH1a1 (Cell Signaling, code 12035, 1:800), goat
anti-GFAP (Abcam, code ab7260,1:2000) or rat–anti
CD133 (a generous gift by Denis Corbeil, Dresden,
Germany, 1:200). Additional immunohistochemistry was
performed using rat-anti-cytokeratin 19 (The Develop-
mental Studies Hybridoma Bank at the University of Iowa,
Iowa City, USA, clone TROMA-III, dilution 1:50), rat
anti-F4/80 (AbD Serotec, Oxford, UK, MCA497, 1:10) or
goat anti-vimentin (Santa Cruz Biotechnology, Santa Cruz,
USA, sc7557, dilution 1:50) antibody. The following
secondary antibodies were used: the Universal LSAB+
Kit/HRP (Dako) for primary goat, rabbit or mouse
antibodies or alkaline phosphatase conjugated anti-rat
(Santa Cruz Biotechnology, sc2021, 1:200) antibody
for primary rat antibodies. All quantifications of cells
or of necrotic areas were performed 120 to 270 μm
from the tumor margin.
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Data presentation and statistics were performed as de-
scribed previously [15]. The significance of differences was
evaluated using a Mann-Whitney rank-sum test, followed
by the correction for the accumulation of the α error by
considering the number of meaningful comparisons. Dif-
ferences with P ≤ 0.05, divided by the number of meaning-
ful comparisons, were considered to be significant.
Results
Characterisation of the syngeneic orthotopic carcinoma
model
To test whether diabetes, chronic pancreatitis or a com-
bination of both influence the pathophysiology of a fully
established PDA, we injected 6606PDA cells into the
head of the pancreas in either diabetic mice (obese) or
normoglycemic (lean) littermates (Figure 1A and B).
Administration of cerulein (Cer) or saline (Sham) in
both genotypes allowed us to compare pathophysiological
parameters in carcinoma during pancreatitis (lean, Cer),
diabetes (obese, Sham), or diabetes with concurrent pan-
creatitis (obese, Cer) to carcinoma in animals without
diabetes or pancreatitis (lean, Sham). We observed thatFigure 1 Characterisation of the syngeneic orthotopic PDA model. (A
of non-diabetic (lean) or diabetic (obese) mice. Chronic pancreatitis was ind
(obese Cer) cohorts of mice three times a day on the indicated days, wher
received 0.9% saline solution. Tissue samples were analyzed on day 20. (B) Th
(C) A representative histology of a PDA reveals necrotic areas (arrowhead), buindependent of treatment or genotype 100% of mice de-
veloped a carcinoma within 20 days. Histological analysis
of the carcinomas revealed vital tissue with partial epithe-
lial morphology, but also necrotic areas within the
tumor (Figure 1C). Obese mice had significantly increased
blood glucose concentrations, when compared to lean lit-
termates (Figure 2A). Successful induction of pancreatitis
by cerulein administration was verified by increased lipase
activity and reduced pancreas weight in cerulein treated
obese as well as lean mice when compared to sham
treated controls (Figure 2B and C). In addition, ceru-
lein administration causes the deposition of collagen I
(Figure 2D) and the expression of α-smooth muscle
actin in periacinar stellate cells (Figure 2E) of lean as
well as obese mice when compared to sham treated an-
imals. The induction of α-smooth muscle actin in cer-
ulein treated lean mice, however, was weaker when
compared to cerulein treated obese mice (Figure 2E).
Diabetes increases tumor size and proliferation of
carcinoma cells
Within three weeks after the injection of adenocarcinoma
cells in the pancreas diabetic obese mice developed) 6606PDA cells were injected on day 0 into the head of the pancreas
uced by ip injection of cerulein in non-diabetic (lean Cer) and diabetic
eas control non-diabetic (lean Sham) and diabetic (obese Sham) mice
e correct injection of carcinoma cells could macroscopically be verified.
t also vital cells with partially epithelial morphology (arrow). Bar = 50 μm.
Figure 2 Characterisation of diabetes and pancreatitis. (A) The average blood glucose concentration of two measurements per mouse (day 0
and day 20) for each cohort is given for sham treated non-diabetic (lean Sham) or diabetic (obese Sham) mice and in cerulein treated non-diabetic (lean
Cer) or diabetic (obese Cer) animals. (B) Comparison of the lipase activity in the blood between the four cohorts indicates induction of pancreatitis on
day 8. (C) Evaluation of the pancreas weight on day 20 indicates pancreatic atrophy after induction of chronic pancreatitis. (D) Immunohistochemistry on
day 20 indicates collagen I deposition (brown colour) in the pancreas after cerulein induced chronic pancreatitis in lean and obese mice. (E) Evaluation of
α-smooth muscle actin expression by immunohistochemistry (brown colour) on day 20 indicates moderate activation of periacinar stellate
cells by cerulein in lean mice and strong activation in obese mice (arrows point at blood vessels, arrowheads point at stellate cells). Box plots
indicate the median, the 25th and 75th percentiles in the form of a box, and the 10th and 90th percentiles as whiskers. The number of animals
evaluated was n = 11 (lean Sham), n = 10 (lean Cer), n = 11 (obese Sham), n = 13 (obese Cer). Significant differences between the cohorts are
indicated, *P ≤ 0.006. Bars = 50 μm.
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normoglycemic lean littermates (Figure 3A). Measuring
the tumor weight revealed significantly larger carcinomas
in sham treated obese mice, when compared to sham
treated lean littermates (Figure 3B). Increased tumor
weight was also observed in cerulein treated obese mice
when compared to cerulein or sham treated lean litter-
mates (Figure 3B). Only a moderate increase in tumorweight was observed in cerulein treated obese or lean
mice when compared to the same genotype of mice,
which received sham treatment (Figure 3B).
To evaluate if diabetes modulates proliferation of cancer
cells, the number of BrdU+ cells within the carcinoma
were evaluated (Figure 3C). Proliferation of cancer cells
was significantly increased in sham treated obese mice when
compared to sham treated lean littermates (Figure 3D).
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treated obese mice when compared to cerulein or sham
treated lean littermates (Figure 3D). These data suggest
that in mice with a diabetes type II like syndrome car-
cinoma cells have a higher proliferation rate resulting
in increased tumor size. In order to evaluate, if the in-
trinsic growth ability of cancer cells changes perman-
ently in obese mice, we re-isolated the cancer cellsFigure 3 Diabetes leads to increased tumor weight and enhanced can
isolated pancreas with a carcinoma shows obvious differences in tumor siz
mice and in cerulein treated non-diabetic (lean Cer) or diabetic (obese Cer
mouse cohorts. (C) Representative images of histological sections after Brd
carcinoma reveals increased proliferation of cancer cells in diabetic mice. B
of a box, and the 10th and 90th percentiles as whiskers. The number of anim
Sham), n = 13 (obese Cer). Significant differences between the cohorts arefrom carcinomas in lean and obese mice and compared
their proliferation rate in vitro. Carcinoma cells, which
were isolated from lean mice, had a very similar prolifera-
tion rate to carcinoma cells, which were isolated from
obese mice (lean: 1.09/1.06-1.14, n = 3; obese: 1.06/0.96-
1.21, n = 6), or 6606PDA cells, which were never injected
in any animal (1.05/0.99-1.21, n = 7; median/interquartile
range of BrdU incorporation measured by ELISA). Thus,cer cell proliferation on day 20. (A) Representative images of
e in sham treated non-diabetic (lean Sham) or diabetic (obese Sham)
) animals. (B) Quantification of the tumor weight in the indicated
U immunohistochemistry. (D) Quantification of BrdU+ nuclei within the
ox plots indicate the median, the 25th and 75th percentiles in the form
als evaluated was n = 11 (lean Sham), n = 10 (lean Cer), n = 11 (obese
indicated, *P ≤ 0.002 (B), *P = 0.005 (D). Bar =1 cm (A) or 50 μm (C).
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manently change the proliferative capacity of tumor cells.
Diabetes does not decrease cell death in carcinomas
In order to evaluate apoptosis, Apoptag+ cells were quan-
tified within carcinomas. No obvious decrease in the num-
ber of Apoptag+ cells in diabetic mice could be observed
when compared to nondiabetic littermates (Figure 4A
and B). Planimetric analysis of H/E stained histological
sections revealed that diabetes did also not reduce the
relative area of necrosis within the carcinomas (Figure 4C
and D).
Characterisation of the cancer stem cell compartment
Cytokeratin 19 and vimentin expression was analysed in
the carcinomas in order to evaluate if injected cancer cells
can give rise to distinct cell types. In tumors, cells with
epithelial morphology expressed the epithelial markerFigure 4 Diabetes does not inhibit cell death in PDA on day 20. (A) R
cell death in the carcinomas of sham treated non-diabetic (lean Sham) or
treated non-diabetic (lean Cer) or diabetic (obese Cer) animals. (C) Repre
of necrotic tissue area in the carcinomas of the indicated mouse cohorts.
form of a box, and the 10th and 90th percentiles as whiskers. The number
(obese Sham), n = 4 (obese Cer) in panel B and n = 7 (lean Sham), n = 7 (l
between the cohorts were not significant. Bar = 50 μm.cytokeratin 19 (Figure 5A), whereas non-epithelial cells
expressed the mesenchymal marker vimentin (Figure 5B).
These data suggest that injected cancer cells can differ-
entiate into at least two different cell types, and that a
pluripotent cell population might be present within the
injected cancer cells. To evaluate if pancreatic cancer
cell lines express cancer stem cell markers such as Aldh1
we compared the expression of Aldh1a1 in pancreatic can-
cer cell lines such as Panc02, 7265PDA and 6606PDA with
the liver metastasis cell line 6606l. The Aldh1a1 protein
was readily observed with an apparent molecular weight
of 55 kDa in all cell lines as well as in kidney cell extract,
used as a positive control (Figure 5C). In some cell lines
the antibody also detected another protein with an appar-
ent molecular weight of 58 kDA, which is possibly
Aldh1a3 or another Aldh family member (Figure 5C). In
carcinomas few cells specifically expressed Aldh1 as evalu-
ated by immunohistochemistry (Figure 5D). The numberepresentative image of an Apoptag+ cell. (B) Quantification of apoptotic
diabetic (obese Sham) mice and in the carcinomas of cerulein
sentative image of a necrotic area. (D) Comparison of the percentage
Box plots indicate the median, the 25th and 75th percentiles in the
of animals evaluated was n = 4 (lean Sham), n = 4 (lean Cer), n = 3
ean Cer), n = 3 (obese Sham), n = 6 (obese Cer) in panel D. Differences
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treated obese mice when compared to sham treated
lean littermates (Figure 5E). A significantly decreased
number of Aldh1+ cells was also observed in cerulein
treated obese mice when compared to cerulein treated
lean littermates (Figure 5E).
We also characterized the expression of an additional
cancer stem cell marker, CD133. This protein was not
detected in the Panc02, 7265PDA and 6606PDA cell lines
by Western Blotting, but was highly expressed in the
6606l cell line and kidney (Figure 6A). However, since a
low level of CD133 mRNA could be detected in 7265PDA
and 6606PDA cells by PCR (Figure 6B), we evaluated if
a few CD133+ cells could be observed in 6606PDA cell
derived carcinomas. CD133 expression could be easilyFigure 5 Analysis of CK19, vimentin and Aldh1a1 expression. (A) Repr
(B) of non-epithelial cells expressing vimentin in 6606PDA derived carcin
and kidney by Western Blotting. An additional band (arrow) is observed in som
family member; e.g. Aldh1a3. (D) Immunohistochemistry of 6606PDA derived
some cancer cells. (E) Quantification of Aldh1+ cells in the carcinomas of sham
the carcinomas of cerulein treated non-diabetic (lean Cer) or diabetic (obese C
in the form of a box, and the 10th and 90th percentiles as whiskers. The numb
(obese Sham), n = 10 (obese Cer). Significant differences between the cohorts
three independent experiments. Bars = 50 μm.observed on the apical membrane of epithelial cells lining
the proximal tubuli of the kidney as published previously
(Figure 6C) [22]. CD133+ cells could also be observed in
few cells of 6606PDA derived carcinomas (Figure 6D).
The number of CD133+ cells was moderately increased
in cerulein treated lean mice when compared to sham
treated lean littermates (Figure 6E). A moderately in-
creased number of CD133+ cells was also observed in ceru-
lein treated obese mice when compared to cerulein treated
lean littermates (Figure 6E). We also analyzed the expression
of GFAP, a protein expressed by glioblastoma and neural
stem cells. GFAP was easily detected by Western Blotting in
Panc02, 7265PDA, 6606PDA, 6606l cells and brain, but only
elusive expression was observed in 6606PDA cell derived
carcinomas by immunohistochemistry (data not shown).esentative images of epithelial cells expressing cytokeratin 19 and
omas. (C) Analysis of Aldh1a1 expression in cultured PDA cell lines
e cell lines and kidney cell extract and might represent another Aldh
carcinomas reveals expression of the cancer stem cell marker, Aldh1, in
treated non-diabetic (lean Sham) or diabetic (obese Sham) mice and in
er) animals. Box plots indicate the median, the 25th and 75th percentiles
er of animals evaluated was n = 9 (lean Sham), n = 9 (lean Cer), n = 9
are indicated, *P = 0.003. The Western Blot results were reproduced by
Figure 6 Analysis of CD133 expression. (A) Analysis of CD133 expression in cultured 6606PDA cells and kidney by Western Blotting. (B) Analysis of
CD133 expression in cultured PDA cell lines and kidney by PCR. (C) The positive control for CD133 immunohistochemistry reveals expression of CD133
(arrow) in epithelial cells of proximal tubuli. (D) Immunohistochemistry of 6606PDA derived carcinomas reveals expression of CD133 (arrow) in some
cancer cells. (E) Quantification of CD133+ cells in the carcinomas of sham treated non-diabetic (lean Sham) or diabetic (obese Sham) mice and in the
carcinomas of cerulein treated non-diabetic (lean Cer) or diabetic (obese Cer) animals. Box plots indicate the median, the 25th and 75th percentiles in
the form of a box, and the 10th and 90th percentiles as whiskers. The number of animals evaluated was n = 5 (lean Sham), n = 4 (lean Cer),
n = 6 (obese Sham), n = 6 (obese Cer). Differences between the cohorts were not significant. The Western Blot results were reproduced by
three independent experiments. Bars = 50 μm.
Zechner et al. BMC Cancer  (2015) 15:51 Page 9 of 13Evaluation of inflammation and the desmoplastic reaction
Since surprisingly little influence of pancreatitis on the
pathophysiology of PDA was observed in our study, we
evaluated, if pancreatitis lead to more infiltrating inflam-
matory cells in the carcinoma. Because cerulein induced
pancreatitis is characterized mainly by infiltrating neutro-
phil granulocytes, the number of CAE+ cells was evaluated
(Figure 7A and B). Indeed, a moderately increased number
of CAE+ cells was detected in the carcinomas of ceru-
lein treated mice compared to sham treated animals
(Figure 7B). Diabetes, however, caused a small reduction
in the number of tumor infiltrating CAE+ granulocytes.
The observed differences were not significant. Similarily, a
moderately increased number of F4/80+ mahrophages was
detected in the carcinomas of cerulein treated mice
compared to sham treated animals (data not shown).
This suggests that strong inflammation in the pancreas
did not automatically lead to a major increase in thenumber of inflammatory cells in the tumor. To verify, if
a desmoplastic reaction by the host might shield the
carcinomas, we injected the 6606PDA cells in C57BL6-
TgACTB-eGFP1Osb/J mice expressing GFP ubiquitously. We
observed that carcinomas were surrounded by GFP+ fibro-
blast like cells (Figure 7C). Quantification of the thickness
of the α-smooth muscle actin positive desmoplastic re-
action surrounding the carcinomas, revealed a moder-
ate increase in the thickness of the desmoplastic reaction
in cerulein treated mice when compared to sham treated
animals (Figure 7D). In diabetic mice this desmoplastic
reaction was moderately reduced (Figure 7D).
Metformin decreases tumor size and proliferation of
carcinoma cells
In order to evaluate if the antidiabetic drug, metformin,
has an effect on PDA, we injected 6606PDA cells into
the head of the pancreas on day 0. From day 8 to 29 one
Figure 7 Analysis of inflammation and desmoplasia on day 20. (A) Representative image of CAE+ inflammatory cells in PDA. (B) Quantification of
CAE+ cells in the carcinomas of sham treated non-diabetic (lean Sham) or diabetic (obese Sham) mice and in the carcinomas of cerulein
treated non-diabetic (lean Cer) or diabetic (obese Cer) animals. (C) Desmoplastic reaction visualized by anti-GFP immunohistochemistry in a
C57BL6-TgACTB-eGFP1Osb/J mouse, which ubiquitously expresses GFP. (D) Quantification of α-smooth muscle+ desmoplastic reaction surrounding
the carcinomas in sham treated non-diabetic (lean Sham) or diabetic (obese Sham) mice and in the carcinomas of cerulein treated non-diabetic (lean
Cer) or diabetic (obese Cer) animals. Box plots indicate the median, the 25th and 75th percentiles in the form of a box, and the 10th and 90th percentiles
as whiskers. The number of animals evaluated was n = 11 (lean Sham), n = 9 (lean Cer), n = 9 (obese Sham), n = 12 (obese Cer) in Panel B and n = 4 for
each cohort in Panel D. Bar = 50 μm.
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cohort was treated with metformin (Figure 8A). Meas-
uring the tumor weight on day 29 revealed significantly
smaller carcinomas in metformin treated mice, when
compared to sham treated littermates (Figure 8B). The
proliferation of cancer cells was also significantly de-
creased in metformin treated mice when compared to
sham treated littermates (Figure 8C). These data sug-
gest that metformin reduces the proliferation rate of
carcinoma cells resulting in smaller tumors.
Discussion
The presented data demonstrate that a diabetes type II like
syndrome i) increases the weight of PDA, ii) stimulates
the proliferation of cancer cells, iii) does not inhibit the
cell death of cancer cells and iv) reduces the number ofAldh1+ cells within the tumor. We observed, however, no
major influence of chronic pancreatitis on the pathophysi-
ology of PDA. In addition presented data demonstrate that
the antidiabetic drug metformin i) decreases the weight of
PDA and ii) reduces the proliferation of cancer cells.
The observed major effect in B6.V-Lepob/ob mice on
the pathophysiology of PDA might be caused by distinct
features of these mice such as hyperinsulinaemia, hyper-
glycaemia or by adipositas. These features are typical for
the early stage of type II diabetes. Alternatively, hyper-
glycaemia and adipositas are also associated with the
metabolic syndrome. Indeed, this mouse strain has been
used as model system for both diseases [23,24]. Neverthe-
less, we favor the idea, that this mouse strain is a model
for type II diabetes rather than for the metabolic disease,
since B6.V-Lepob/ob mice do have increased high-density
Figure 8 Metformin reduces tumor weight and cancer cell
proliferation. (A) 6606PDA cells were injected on day 0 into the
pancreas of C57BL/6J mice. Between day 8 and day 29 PBS (Sham)
or metformin was ip injected daily and tissue samples were analyzed
on day 29. (B) Quantification of the tumor weight in the indicated
mouse cohorts. (C) Quantification of BrdU+ nuclei within the carcinoma
reveals that metformin treatment reduces cell proliferation. Box plots
indicate the median, the 25th and 75th percentiles in the form of a box,
and the 10th and 90th percentiles as whiskers. The number of animals
evaluated was n = 8 (Sham) and n= 7 (metformin), Significant differences
between the cohorts are indicated, *P = 0.004 (B), *P = 0.029 (C).
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diet-induced atherosclerosis [23]. Since this mouse strain
is characterized by a 10-fold higher C-peptide level but by
only about a 2-fold higher glucose concentration in the
blood [15], it is likely that hyperinsulinaemia rather than
hyperglycemia stimulates cancer cell proliferation and
increases the tumor weight. This hypothesis is sup-
ported by experimental studies indicating that strepto-
zotocin induced type I like diabetes, which is characterized
by higher blood glucose concentration but lower insulin
concentration, does not increase tumor weight in pancre-
atic carcinomas [25]. In addition, the observation that hu-
man pancreatic cancer cell lines express insulin receptor
and that the proliferation of these cell lines is induced by
insulin also supports this conclusion [26,27]. High concen-
trations of insulin can also activate the IGF-1 receptor [28].
This receptor and its adaptor proteins IRS-1 and IRS-2 are
expressed in pancreatic cancer cell lines as well as in hu-
man PDA [29-31]. These data underscore the importance
of these signaling pathways in promoting pancreatic cancer
cell proliferation and suggest that blocking the IGF-I recep-
tor might be a valuable approach for targeted therapy ofpancreatic cancer. In fact, Ganitumab, a monoclonal IGF-1
receptor antibody, inhibited growth of pancreatic carcin-
oma xenografts in mice and showed tolerable toxicity and
trends toward an improved 6-month survival rate in pa-
tients with metastatic pancreatic cancer [32,33].
Our data indicate that diabetes type II like syndrome
increases tumor weight, but at the same time decreases
the number of Aldh1+ cells. Since Aldh1 expression is
a feature of cancer stem cells in pancreatic carcinoma
[7-9,34,35], it is tempting to speculate that diabetes in-
duces the differentiation of Aldh1+ quiescent cancer
stem cells into fast proliferating Aldh1− cells, which
might contribute to increased tumor weight. This in-
terpretation is consistent with the concept of quies-
cence of cancer stem cells and some adult stem cells
[36,37]. Interestingly, insulin/IGF receptor signaling has
been reported to abrogate the quiescent state of stem cells,
which underlines our hypothesis that hyperinsulinemia in-
creases cell proliferation in PDA [38]. However, it is also
possible that Aldh1+ cells might not be true cancer stem
cells in this animal model and that the reduced number of
Aldh1+ cells in diabetic mice reflects how diabetes in-
fluences cancer cell plasticity in a cancer stem cell inde-
pendent manner. It is also worth noticing that another
so called tumor stem cell marker, CD133, can be observed
in the carcinomas, but that the quantification of CD133+
cells does also not correlate well with tumor size. Since it
has been suggested that chemotherapy resistance might be
caused by cancer stem cells, we compared the expression
of CD133 and Aldh1 between three gemcitabine resistant
6606PDA clones and the original gemcitabine sensitive
6606PDA cell line. These gemcitabine resistant clones did
not express higher levels of Aldh1 or CD133 (data not
shown). Possibly, Aldh1 or CD133 expression does not in
all cases directly correlate with tumor size or chemoresis-
tance and might also not always define cells with stem cell
properties [39]. This interpretation is supported by the fact
that these proteins are readily expressed by fully differenti-
ated cells. For example, CD133 is expressed in epithelial
cells of proximal tubuli in the kidney and Aldh1 is highly
expressed in the epithelium of the intestine, in liver and in
pancreas [22,40].
In contrast to diabetes type II, chronic pancreatitis had
little influence on the pathophysiology of the carcinomas.
This result is surprising considering the published consen-
sus that chronic inflammation is a major risk factor for the
development of PDA [10,11,14]. The following interpreta-
tions may explain this discrepancy: i.) Chronic inflamma-
tion might promote cancerogenesis at an early stage of
PDA development, but might have little influence on
advanced adenocarcinomas. This interpretation is con-
sistent with data indicating that chronic inflammation
increases the risk for developing precancerous lesions
and PDA in humans as well as in genetically modified
Zechner et al. BMC Cancer  (2015) 15:51 Page 12 of 13mice [10,16,17]. This hypothesis is also supported by
publications, which demonstrate that anti-inflammatory
drugs delay the progression of pancreatic cancer precursor
lesions [41], but fail to have any benefit in the therapy of
PDA [42]. ii.) Alternatively, chronic pancreatitis had little
influence on the pathophysiology of the carcinomas,
because of limitations of our animal model. Although
we were able to induce a strong chronic pancreatitis by
redundant administration of cerulein (Figure 2 B-E), we
observed some local inflammation adjacent to the car-
cinoma and a strong desmoplastic reaction, independent
of the induction of pancreatitis (data not shown and
Figure 7). Possibly, this desmoplastic reaction shields
the carcinomas from local inflammation or the observed
peritumoral pancreatitis may have blunted the effects of
cerulein. If the pathophysiology of a fully established pan-
creatic adenocarcinoma is influenced by pancreatitis or
intra- and peritumoral inflammation, which is detected in
most PDAs, is currently of intellectual as well as of clinical
interest [14]. Our data indicate that a strong inflammatory
milieu does not automatically lead to major changes in
cancer cell proliferation, cell death or tumor size. How-
ever, a similar study with genetically modified mouse
models of PDA needs to be pursued in order to exclude
the possibility, that the observed effects are mouse model
specific.
Conclusion
In conclusion, these experiments provide support for the
concept that a diabetes type II like syndrome promotes
growth of PDA, whereas strong inflammation does not
have a major influence on the pathophysiology of advanced
PDA. Our data also demonstrate that an anti-diabetic
medication such as metformin has anti-tumorigenic
properties, which is consistent with recently published
data on human PDA cells [43,44]. If this anti-tumorigenic
effect will also be observed in clinical trials, which are cur-
rently pursued, remains to be seen (https://clinicaltrials.
gov/) [45]. In addition, modulation of inflammation for the
therapy in pancreatic cancer is a goal in several clinical and
preclinical studies [14]. However, our data support the idea
that modulation of cell metabolism might be more promis-
ing than modulation of inflammation for the treatment of
PDA [14,46].
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